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ABSTRACT 
 
Dietary Polysaccharides Differentially Stimulate the Proliferation of Native 
Gastrointestinal Bacteria.  (August 2010) 
Carly Marie Ferguson, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Joseph M. Sturino 
  
 
 We determined the extent to which consumption of four diets containing mixtures 
of three non-digestible but fermentable polysaccharides preferentially stimulated the 
proliferation of gastrointestinal bifidobacteria and lactobacilli in vivo.  Seven-week old 
Sprague-Dawley rats were fed corn oil diets supplemented with: 6% (w/w) cellulose; 2% 
(w/w) cellulose combined with 4% (w/w) soluble corn fiber; 2% (w/w) cellulose 
combined with 4% (w/w) resistant starch; or 2% (w/w) cellulose combined with 2% 
(w/w) soluble corn fiber and 2% (w/w) resistant starch diets for 43 days; fecal samples 
were collected weekly.  Quantitative real-time polymerase chain reaction (PCR) using 
taxon-specific 16S ribosomal RNA (rRNA) gene primers was used to determine the 
number of 16S rRNA gene copies per gram of feces (16S rRNA gene copies/g feces).  At 
the end of the 43-day in vivo experiment, consumption of a resistant starch (R) diet 
resulted in a 26.54-fold increase in bifidobacteria, as measured by 16S rRNA gene 
copies/g feces (p = 0.000). 
We also examined the ability of 9 lactobacilli and 11 bifidobacteria strains to 
utilize resistant starch and soluble corn fiber in vitro.  Strains were cultivated on Garche 
agar plates containing 1% soluble corn fiber or 1% resistant starch to examine growth 
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capabilities. Five strains of bifidobacteria were cultivated in bacteriological media 
supplemented with resistant starch or lactose as the sole carbon source.  Plate counts were 
used to test the hypothesis that utilization of carbon source is species-dependent, as well 
as to compare growth capabilities of Bifidobacterium longum NRRL B-41409 and 
Bifidobacterium bifidum NRRL B-41410.   
All bifidobacteria and lactobacilli strains tested successfully utilized soluble corn 
fiber and resistant starch in vitro, although degree of growth varied.  Plate count studies 
revealed that Bifidobacterium longum DJ010A, Bifidobacterium bifidum NRRL B-41410, 
and Bifidobacterium animalis subspecies animalis NRRL B-41406 all showed a 
significant increase in colony forming units when fermenting resistant starch (1.5107 – 
6.47107 CFU/mL). Bifidobacterium bifidum NRRL B-41410 exhibited stronger growth 
than Bifidobacterium longum NRRL B-41409 during consumption of resistant starch and 
soluble corn fiber.  These results indicate that regular consumption of resistant starch may 
increase the number of colonic commensal bifidobacteria, and the utilization of resistant 
starch by bifidobacteria and lactobacilli is species and strain-dependent. 
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ATP                            Adenosine Triphosphate 
           
B.                                Bifidobacterium 
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PAD Pulsed Amperometric Detection 
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rrn Ribosomal RNA 
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RS3                             Retrograded Resistant Starch 
 
RS4                            Chemically Modified Resistant Starch 
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SCFA Short Chain Fatty Acid 
 
Spp Plural of Species 
 
Subsp. Subspecies           
 
Tris                              Tris(hydroxymethyl)aminomethane   
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CHAPTER I 
INTRODUCTION 
 
Bacteria play an astounding role in the daily lives of the human host.  While 
many are aware of bacterial involvement in food production or their ability to cause 
infection, few realize what an important role microorganisms play in maintaining human 
health and gastrointestinal function.  In 1683, van Leeuwenhoek first discovered bacteria 
in human plaque samples using a homemade microscope, which he then termed 
“animalcules” [van Leeuwenhoek, 1683]. van Leeuwenhoek‟s discovery set the stage for 
over 300 years of scientific research in the field of gastrointestinal microbiology.   
 In 1977, it was hypothesized that human adults are composed of approximately 
1014 cells; of these, only 10% are of human lineage (1).  As molecular techniques 
advance, it was recently estimated that approximately 1018 microbial cells inhabit the 
human body (2).  Bacteria inhabit various mucosal surfaces of the human body (e.g., 
skin, oral cavity, upper respiratory tract) with the vast majority residing in the 
gastrointestinal tract (3).  Bacteria are so numerous in this region that one gram of large 
intestinal contents contains approximately 150 times more bacteria than there are 
humans on the planet (4).   
The microbiome (i.e., total number of genes encoded by all bacterial genomes 
residing in the same habitat) in the human host is even thought to exceed that of the 
human genome by at least one order of magnitude (5, 6).  This information has caused  
___________ 
This thesis follows the style of The Journal of Nutrition. 
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many to ponder: who is ultimately controlling human function, the inhabitants or the 
host?  
While the relationship between bacteria and their host has often been described 
as commensal (i.e., one partner benefiting without positively or negatively affecting the 
other partner), some researchers contend that a mutualistic or symbiotic relationship 
exists, with interdependent host and flora mutually benefiting from one another (7, 8).  
As will be discussed, the hosts‟ benefits of a healthy bacterial population are numerous, 
ranging from increased nutrient utilization to protection against pathogenic bacteria (9). 
 Bacterial populations found in the human gastrointestinal tract vary between 
individuals, intestinal location, and age groups (10), and can be affected by various 
factors, as indicated by Table 1 (11).  The ability to manipulate the gastrointestinal 
microbiota through modulation of external factors has introduced a new approach to 
influencing human health.  The following literature review will focus primarily on two 
exogenous factors that have a profound affect on bacterial growth and activity in vivo: 
dietary intake and gastrointestinal ecology.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3 
 
CHAPTER II 
 
LITERATURE REVIEW 
 
Bacterial Colonization of the Gastrointestinal Tract 
The gastrointestinal tract consists of the mouth, esophagus, stomach, small 
intestine, large intestine, rectum, and anus.  In its entirety, the adult gastrointestinal tract 
is approximately seven meters long (12).  The surface area of the gastrointestinal tract is  
roughly 300 m2, due largely in part to the extensive folds and finger-like extensions 
found in the small intestine (12).  Surface area plays a large role in the functionality and 
efficiency of the gastrointestinal tract, ensuring maximal absorption of nutrients as food 
particles are transported from the stomach to the rectum.  Gastrointestinal tissues aid in 
the breakdown of food particles, as well as the excretion of waste products from the 
body (13). 
 The upper gastrointestinal tract (consisting of mouth, esophagus, and stomach) 
plays a key role in the mastication and digestion of nutrients (11).  While a small subset 
of bacterial species have been shown to inhabit these regions, the majority of bacterial 
colonization occurs in the lower gastrointestinal tract, which consists of the small 
intestine and large intestine (11, 14, 15).  Multiple factors, including pH, peristalsis, 
oxidation-reduction potential, bacterial adhesion, nutrient availability, and diet affect the 
nature of bacteria able to colonize these regions (16).  For example, while gram positive 
species, chiefly lactobacilli and streptococci, are able to colonize the human stomach, the 
total stomach content is usually quite low (<103 CFU/g) as a result of low pH and 
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peristalsis (i.e., involuntary waves of contractions along the gastrointestinal tract) (11, 
17, 18).  While the upper gastrointestinal tract plays an imperative role in improving 
bacterial utilization of nutrients via food degradation and hydrolysis, this review will 
focus on how bacteria utilize available nutrients in the lower gastrointestinal tract. 
 
The Small Intestine 
 The small intestine is roughly 5 to 6 meters long (12).  It is subdivided into three 
sections: the duodenum, jejunum, and ileum (13).  The wall of the gastrointestinal tract 
is composed of four distinct layers, the serosa (outermost layer), muscularis, submucosa, 
and mucosa (innermost layer) (13).  The mucous epithelial layer, the innermost layer of 
the mucosa, consists of fingerlike projections known as villi and microvilli, which aid in 
the absorption of nutrients by vastly increasing surface area (13).   
 The mucous epithelial layer comes in contact with a variety of food sources and 
bacterial populations; therefore it must be equipped for both absorption and immune 
function (10).  The epithelium consists primarily of a layer of absorptive columnar 
epithelial cells for nutrient uptake, but also contains goblet cells that secrete mucus to 
form a physical barrier between foreign bodies and host cells. 
 The body‟s primary immune defense is its placement of lymphatic tissue, which 
contains dense accumulations of small white blood cells (e.g., lymphocytes) that 
specialize in immune function (19, 20).  The human intestine contains the largest mass 
of lymphoid tissue in the body (commonly referred to as gut-associated lymphoid tissue, 
or GALT), and contains more than 106 lymphocytes per gram of tissue (21).  Intra-
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epithelial lymphocytes are categorized as T cells, which identify pathogens through 
„non-self‟ antigen presentation, and elicit an immune response upon the body‟s own cells 
to eliminate an impending threat (20). 
  Lymphatic tissue is typically located in regions prone to bacterial or viral 
infection; therefore it is prevalent in the gastrointestinal tract.  Host-bacterial interactions 
occur at the mucosal layer, where enteric bacteria attach to the mucus layer of the 
luminal side of the epithelium, forming microcolonies (2).  It is through the use of intra-
epithelial lymphocytes that the host is able to detect pathogenic antigens, therefore 
distinguishing which bacteria the host will allow to colonize, and which will be 
removed. 
 The ileocecal region sustains the highest level of growth in the small intestine, 
with bacterial counts in the ranging from 104 CFU/mL to 106-107 CFU/mL contents (18).  
Due to the rapid transit time of its contents and the high pH of bile and pancreatic fluids 
secreted from the stomach, the proximal small intestine exhibits limited growth (18).  
The jejunum is dominated by genus Streptococcus, though it tends to have a diverse 
composition and phylogenetic distribution when compared to other regions of the 
gastrointestinal tract (2, 22). 
  
The Large Intestine 
 Traditionally, the large intestine was viewed as a segment of the digestive tract 
responsible for solute conservation and waste disposal.  It is now known that the large 
bowel facilitates a vast array of bacterial processes that greatly benefit the host.  For 
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example, while the large intestine does compact fecal waste and absorb water, it also 
absorbs vitamins and short chain fatty acids (SCFA) produced by bacteria, providing 
energy to colonocytes (23). 
 Bacterial numbers increase considerably (>108 CFU/mL) in the cecum of the 
large intestine as compared to bacterial growth in the distal ileum (11, 24).  The majority 
of gastrointestinal bacteria reside in the large intestine, which is broader in 
circumference than the small intestine, and is typically 150 cm long (3, 7).  Commonly, 
the large intestine contains 220 grams of gastrointestinal contents, creating an average 
daily output of 120 grams of fecal waste (25).  Research has shown that in humans 
consuming a western diet, roughly half of the colonic contents is composed of microbial 
biomass (26, 27). 
 The large intestine is more conducive to bacterial growth than the small intestine 
for several reasons.  While the average transit time in the human small intestine ranges 
from 2-4 hours, the transit time in the large intestine is generally between 24-72 hours 
prior to excretion (28).  As food particles pass through the ileocecal sphincter, the transit 
of gastrointestinal content decreases, allowing bacteria more time to utilize the food 
matter and develop bacterial communities (29).  Gastrointestinal pH is also markedly 
increased in comparison to the stomach (pH ~ 2) and proximal small intestine (pH ~ 5-
7), which also promotes bacterial proliferation (28).  Substrate availability tends to be 
higher in the proximal colon, with concentrations decreasing towards the rectum (18). 
 Permanent colonization primarily occurs in the large intestine, where bacterial 
populations can often reach 1011 to 1012 CFU/g (4, 18).  Roughly 40 species compose 
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99% of all autochthonous (i.e., indigenous) bacterial isolates found in the large intestine, 
which tends to suggest that growth conditions are somewhat selective, only allowing a 
handful of microbiota to permanently colonize (4).  One such selective trait is the large 
intestine‟s lack of available oxygen, which allows anaerobes, such as bifidobacteria, 
bacteroides, and eubacteria to dominate this niche (26, 28).  Bacteria that permanently 
colonize the gastrointestinal tract are generally believed to be catabolically diverse, 
meaning that they can successfully utilize a wide variety of compounds for energy.  
Since levels and varieties of nutrients passing through the gastrointestinal tract fluctuate 
on a daily basis, autochthonous bacteria must be able to thrive on multiple carbon 
sources to maintain colonization. 
 The large intestine is composed of two major regions: the cecum and colon.  The 
cecum is a small pouch that accumulates digestive contents as it exits the ileocecal 
sphincter and enters the large intestine.  Facultative anaerobes account for roughly one-
fourth of all bacteria in this region, with the predominate bacterial genera found in this 
region being Escherichia, Enterococci, and Lactobacillus (30).  Bacterial colonization 
increases in the colon, with most bacteria classified as non-sporeforming anaerobes.  
Bacteroides and Clostridium dominate this region, although other common genera 
include Bifidobacterium and Eubacterium, among others (22, 31).  It is believed that 
Bacteroides account for at least 30% of all anaerobes present in the colon, while 
Bifidobacterium are thought to account for 25% (31). 
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Fermentation 
 Bacterial colonization impacts host health in a variety of ways, many of which 
are attributable to bacterial fermentation.  In order to survive in the human 
gastrointestinal tract, bacteria must be able to utilize colonic contents as a source of 
carbon, nitrogen, sulphur, and phosphorus.  Through the process of fermentation, both 
aerobic and anaerobic bacteria derive energy through the oxidation of organic 
compounds (32).   
 During fermentation, glucose molecules are oxidized into two molecules of 
pyruvate, which are further catabolized into various end products depending upon 
bacterial type.  Due to a lack of oxygen, substrate-level phosphorylation is used to net 2 
ATP, with NAD+ acting as an electron acceptor (32).  Fermentation is regulated by the 
need to maintain redox balance, which is achieved through the reduction or oxidation of 
nucleotides (4).  While aerobic bacteria require an environment with a positive reduction 
potential, anaerobic bacteria can only be active in a negative reduction potential 
environment (facultative anaerobes may adjust their metabolism based upon their 
environment) (33).   
 Numerous products can be formed during fermentation, most notably short chain 
fatty acids and gases.  Short chain fatty acids are organic anionic molecules which range 
from 1 to 6 carbons atoms (34).  During carbohydrate fermentation, saccharolytic 
bacteria produce a variety of SCFAs, although butyrate, lactate, and acetate predominate 
(35).  Proteolytic bacteria form a variety of branched chain fatty acids, such as 
isobutyrate, 2-2-methyl-butyrate, and isovalerate, as well as phenols, indoles, and amines 
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(35).  While a significant producer of protein end products, protein fermentation only 
contributes approximately 5% of all SCFA found in the gastrointestinal tract (36, 37).  
Gases such as H2, CO2, and CO4 are also common byproducts in both scenarios (35, 37). 
 Once generated, SCFAs are quickly absorbed by epithelial cells (35).  The 
concentration gradient formed between the colonic lumen and blood favors the 
movement of SCFAs through the epithelial cells and into the blood compartment (38).  It 
is estimated that 95-99% of SCFAs formed by gastrointestinal bacteria are absorbed by 
the host, suggesting that the host greatly benefits from these byproducts (4).  Once 
absorbed, SCFAs are metabolized by colonocytes via -oxidation, acting as a significant 
colonocyte fuel source, with butyrate being most efficiently utilized (38).  SCFAs and 
their metabolites enter hepatic circulation and pass through the liver before being 
metabolized by muscle cells.  Few SCFAs are lost in urine output, and as previously 
mentioned, very little is lost in fecal contents (35).  End-products of fermentation can 
also appear in both blood and breath, which can be another indicator used to study 
intraluminal events, such as utilization of dietary carbon sources (31). 
 Bacterial growth and metabolism tend to be more efficient in locations where 
transit time of contents is high, which can cause the pH to decrease as a result of high 
SCFA concentrations (4, 38).  Fermentation primarily occurs in the cecum and proximal 
colon, where substrate availability and transit time are high (34).  As such, SCFA levels 
in the proximal colon are approximately 70-140 mM, while only 20-70 mM in the distal 
colon (36).  Therefore, measures of SCFA production in one region cannot be 
generalized to represent the entire large intestine (39, 40). 
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 The products of fermentation, especially short chain fatty acids, have many 
favorable effects on the human host.  Aside from providing nutrients to the colonic 
epithelium and aiding in overall immune health, SCFAs modulate colon and intracellular 
pH, as well as cell volume (41).  SCFAs also stimulate the absorption of sodium and 
water through sodium/hydrogen ion exchange (35, 38, 41).  Studies have also found that 
SCFA, chiefly butyrate, may be associated with a reduced risk of certain gastrointestinal 
diseases, while also reducing cancer risk (42).  
 Dietary intake is a key variable in gastrointestinal health.  SCFA production 
varies based upon available substrate (34).  As such, dietary intake, such as non-
digestible carbohydrate, is the key regulator of SCFA production (38).  Of all SCFAs, 
butyrate levels tend to vary most in response to dietary changes, primarily in relation to 
starch consumption (35).  Quantitatively, carbohydrate plays the largest role in SCFA 
production, though other sources include protein, peptides, and glycoprotein precursors 
(36, 43).   
  
Short Chain Fatty Acids 
 The ratio of acetate, propionate, and butyrate produced by the gastrointestinal 
microbiota is approximately 60:20:20, respectively (44).  Acetate is the principle short 
chain fatty acid produced during fermentation, with an energy value estimated to be 1.5-
2 kcal/g  (35, 45).  This is the principle byproduct of non-digestible carbohydrate, and is 
absorbed by the epithelium for entrance into portal blood.  Once in circulation, acetate 
passes through the liver to peripheral tissues, where it is metabolized by the muscle cells 
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(35).  Acetate is the primary substrate for endogenous cholesterol synthesis, and is 
associated with increased ATP production (46). 
 Propionate is the major glucose precursor in ruminant species, though not a 
major player in human hindgut fermentation (35).  It is primarily produced via fixation 
of carbon dioxide to form succinate, which is decarboxylated by the dicarboxylic acid 
pathway, though propionate may also be formed from lactate or acrylate precursors via 
the acrylate pathway (47).  This SCFA plays a key role in glucose metabolism, acting as 
both a substrate and inhibitor of gluconeogenesis (34).  Whereas acetate is known for its 
role in cholesterol synthesis, propionate has been found to reduce cholesterol levels in 
both rats and pigs (35).  Mainly cleared by the liver, propionate has little effect on 
human carbohydrate metabolism (35). 
 Butyrate plays a large role in the regulation and growth differentiation of 
colonocytes.  With 70 to 90% of butyrate produced metabolized by colonocytes (41), 
butyrate acts as the primary energy source for colonic epithelium (48).  It is believed that 
increased SCFA production (chiefly butyrate) may play a role in the prevention of 
gastrointestinal disorders, as studies have shown that decreased butyrate-producing 
bacteria may be inversely correlated with incidence of antibiotic-associate diarrhea (34, 
49).   
 Fecal samples are poor indicators of short chain fatty acid production, as it is 
estimated that only 5% are recovered in stool samples (36).  In addition, SCFA levels in 
fecal samples are easily altered by increased fecal bulking or decreased transit time, both 
of which can create the appearance of an increase in SCFA production, when in actuality 
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production is constant (34).  While the information received through this method does 
represent the quantitative majority of bacteria in the human gastrointestinal tract, it is 
difficult to gauge growth in areas such as the small intestine and esophagus, which may 
also be experiencing turnover in bacterial populations. 
 
Symbiotic Species (spp.) 
 Lactobacilli belong to the phylum Firmicutes, class Bacilli, order 
Lactobacillales, and family Lactobacillaceae (50).  The genus Lactobacillus is 
comprised of 113 recognized species and 16 subspecies, with a large variety of 
phenotypic and biological properties (50).  Classified as facultative anaerobes, 
lactobacilli have the ability to create ATP through aerobic respiration when oxygen is 
present, yet are also capable of utilizing fermentation when conditions become anaerobic 
(32). 
 Bifidobacteria are gram positive bacteria, often occurring as Y- or V-shaped rods 
(51).  While bifidobacteria also form lactic acid as a product of carbohydrate 
fermentation, they are not classified as lactic acid bacteria.  Based on rRNA sequence 
data, it was determined that gram positive bacteria form two lines of descent, which are 
categorized based upon the mol percentage of G+C content.  Lactic acid bacteria are 
characterized as having a DNA G+C content of less than 50% and belonging to the 
Clostridium branch, while bifidobacteria have a much higher DNA G+C content of 55-
67%, thus belonging to the Actinomyces branch (52, 53).  Bifidobacteria belong to the 
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phylum Actinobacteria, class Actinobacteria, order Bifidobacteriales, and family 
Bifidobacteriaceae (2). 
 
Lactobacillus spp. 
 While the fetal gastrointestinal tract is believed to be sterile prior to birth, 
inoculation occurs by a variety of environmental sources, including exposure to maternal 
fluids during birth or during the introduction of breast milk (54, 55).  The genus 
Lactobacillus is composed of gram positive rods, which are present in the human 
gastrointestinal tract shortly after parturition (31).  The infant gastrointestinal tract is 
highly variable in its composition, and tends to fluctuate over time (54).  A recent 
analysis of the newborn gastrointestinal microbiota found that bacteria-bacteria 
interactions play a key role in early colonization of the gastrointestinal tract, competing 
with one another for nutrients and adhesion space (56).  The “adult-like” profile of 
lactobacilli populations within one subject tends to remain relatively simple with little 
strain variation after the cessation of breastfeeding and introduction of solid foods (57).  
Lactobacilli are also a large component of the gastrointestinal microbiota of other 
species as well, including mice, rats, pigs, and many fowl species (57).  Certain 
Lactobacillus strains have the ability to adhere to non-secretory epithelial cells of the 
proximal digestive tract of rodents, allowing these bacteria to avoid wash-out during 
digestion and maintain high lactobacilli levels throughout the gut (17).  Lactobacilli 
prefer habitats high in soluble carbohydrates, where degraded protein and vitamins exist 
in conjunction with low oxygen tension (50, 58).  While prominent in the small and large 
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bowel, lactobacilli have also been isolated from the oral cavity and vaginal walls of 
humans, where they dominate the microbiota (59).  While found in all sections of the 
gastrointestinal tract, they are predominant in the upper regions, where they ferment 
simple mono-, di-, and trisaccharides (28, 60).    
 Lactobacilli produce lactic acid as their primary end-product of carbohydrate 
fermentation; therefore they are often referred to as lactic acid bacteria.  These gram-
positive bacteria produce more than 1 milliequivalent of lactic acid per 100 milliliters of 
culture during fermentation, creating an acidic environment which is inhibitory to other 
bacterial populations (17, 52).  The most important genera of lactic acid bacteria include 
Lactococcus, Entercoccus, Streptococcus, Pediococcus, Leuconostoc, Weissella, 
Carnobacterium, and Tetragenococcus (52).  This bacterial faction is characterized by 
an increased tolerance to low pH, and is generally linked to processes such as food 
fermentation and the inhibition of spoilage agents (61). 
 Lactobacilli generally require carbohydrates for energy, and may be either 
homofermentative or heterofermentative (62).  Carbohydrate fermentation occurs 
through two major pathways, both of which are coupled with substrate level 
phosphorylation for the production of ATP (50).  Homofermentative species utilize the 
Embden-Meyerhof pathway, most commonly referred to as glycolysis.  This pathway 
converts one molecule of glucose into two molecules of pyruvate, while simultaneously 
producing the reducing equivalent NADH.  In the absence of oxygen, pyruvate and 
NADH are solely reduced to lactic acid and NAD+, via the enzyme lactic acid 
dehydrogenase (63). Heterofermentative species commonly utilize the 6-
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phosphogluconate pathway for carbohydrate fermentation, which is commonly referred 
to as the Pentose Phosphate Pathway (50).  Unlike the Embden-Meyerhof Pathway, the 
6-phosphogluconate pathway produces a variety of end-products, including lactic acid, 
carbon dioxide, and ethanol.  Through a series of enzymatic reactions, glyceraldehyde-3-
phosphate is formed, which is metabolized to lactic acid in a process similar to the 
glycolytic pathway.  Acetyl-phosphate is also formed in this pathway, and is 
metabolized into the byproduct ethanol (64).   
 
Bifidobacterium spp. 
 Like lactobacilli, bifidobacteria are also present shortly after birth and are 
thought to provide a protective effect against infection during the first days of life (31, 
58, 65).  Bifidobacteria are the largest group of bacteria in infants, and by adulthood, 
constitute roughly one-fourth of all anaerobic species (4).  Levels of bifidobacteria 
colonization are highly affected by environmental factors, such as mode of delivery, type 
of infant feeding, hospitalization, gestational age, and antibiotic use.  Newborns that 
were born vaginally in a home setting with exclusive breastfeeding are more likely to 
harbor high levels of bifidobacteria than those born in a hospital via cesarean section, or 
newborns receiving infant formula (66, 67).   
 The genus Bifidobacterium contains 30 species (2).  Bifidobacteria commonly 
inhabit the intestines and oral cavity of mammals (2, 68), sewage (69, 70), and the insect 
gut (71).  In the human gastrointestinal tract, bifidobacteria tend to colonize lower 
regions, such as the large intestine, where conditions are strictly anaerobic (68, 72).  
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While both lactobacilli and bifidobacteria have the ability to ferment simple sugars, 
bifidobacteria are also able to ferment a variety of complex polysaccharides that have 
escaped human digestion and are abundant in the distal gut (72).  Bifidobacteria are 
classified as saccharoclastic, meaning they produce lactic and acetic acids without 
generating carbon dioxide (73).  Carbohydrate fermentation is achieved exclusively 
through the fructose-6-phosphate shunt, with lactic acid and acetic acid produced as end-
products (74). 
 
Quantification of the Intestinal Bacteria 
 The use of animal studies has allowed researchers to directly quantify bacteria 
from various regions of the gastrointestinal tract via euthanasia and extraction of the 
gastrointestinal tract.  Gathering samples from many regions of the human 
gastrointestinal tract is difficult and often infrequent; therefore many bacterial 
quantification studies have relied on the use of fecal samples.  While bacterial DNA can 
be retrieved and quantified in feces, there is a distinct difference between fecal and 
mucosal microbiota (38).  The majority of bacterial populations found in fecal samples 
represent species known to inhabit the distal large intestine, giving researchers little 
information on bacteria that colonize the proximal regions of the gastrointestinal tract 
(11).   
 Quantitative real time polymerase chain reaction (qPCR) is a method commonly 
used to quantify bacterial populations by amplifying specific regions of a DNA strand 
(75).  This versatile tool can be used to quantify DNA sequences isolated from fecal 
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samples, allowing for a non-invasive quantification of bacterial groups present in the 
distal large intestine.  In order to amplify DNA specific to the bacteria being studied, 
primers must be created that correspond with a region of DNA unique to this bacterial 
group (75).  The 16S ribosomal RNA (rRNA) gene is a region of DNA highly conserved 
among all bacteria, yet contains both conserved and variable regions (76).  Primers can 
be developed to amplify specific sections of the 16S gene, allowing the primers to 
specifically quantify bacterial DNA containing this section.  It is therefore possible to 
create group-specific primers by finding a common gene sequence among their various 
16S regions (76). 
 The 16S rRNA-specific g-bifid-F and g-bifid-R primers used in the 
quantification of our fecal samples were originally developed for the analysis of human 
intestinal bifidobacteria via qPCR (77).  This primer set is specific to the 
Bifidobacterium genus, and creates amplicons 550 base pairs in length (77).  Primers g-
bifid-F and g-bifid-R have also been used in qPCR analyses of human bifidobacteria 
populations throughout the lifespan (78-85), as well as reverse transcription-quantitative 
PCR (RT-qPCR) analysis of human fecal samples (86, 87).  The 16S rRNA-specific 
Lac1 and Lac2 primers used for quantification of lactobacilli were initially designed for 
the detection of the Lactobacillus group in human feces, both through qPCR and 
denaturing gradient gel electrophoresis (DGGE) (88).  While able to detect lactobacilli, 
these primers are also capable of annealing to Pediococcus spp., Leuconostoc spp., and 
Weissella spp. (88).  The Lac1 and Lac2 primers have been used in a variety of real-time 
  
18 
quantitative PCR analyses of the human microbiota (86, 89-100), as well as for 
lactobacilli quantification in fermented food products (101-104). 
 
Benefits of a Healthy Gastrointestinal Tract 
 Humans reap numerous benefits from the company of certain symbiotic bacterial 
populations, notably lactobacilli and bifidobacteria.  As previously mentioned, one 
important function of the gastrointestinal microbiota is the salvaging of nutrients from 
carbohydrates and proteins that would otherwise be lost in feces (5, 6, 18, 105).  These 
metabolic functions also result in the production of vitamin K and B vitamins, as well as 
aid in the absorption of minerals such as calcium or magnesium (106).  Twenty-one 
genera have been identified as B12-producing species, which naturally provide the 
human host with its daily requirement of this essential vitamin (107).  While proteins are 
utilized during fermentation, primary substrates include resistant starches, non-starch 
polysaccharides (NSP), non-digestible oligosaccharides, and sugar alcohols (18).   
 While microbes play a key role in salvaging energy sources, they also perform 
various functions to improve host immune defense against pathogens (2, 5, 9).  An 
increased level of pathobionts (i.e., commensal bacteria with pathogenic potential) has 
been linked to several gastrointestinal disorders, namely inflammatory bowel disease 
(108, 109).  Therefore, it is imperative that a healthy gastrointestinal tract is maintained 
to limit the effects of harmful bacterial species. 
 Through their colonization of the gastrointestinal tract, beneficial bacteria create 
a physical barrier to restrict the growth of pathobionts (106).  Colonization of probionts, 
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such as lactobacilli and bifidobacteria, upregulates mucin gene expression, promoting 
the colonization of symbiotic bacteria while discouraging the adhesion of pathobionts (2, 
110).  The excretion of mucin, which are high molecular weight glycoproteins produced 
by epithelial cells, is stimulated by the binding of probiotic bacteria to specific receptor 
sites on the epithelial cells (111).  Mucin production is also enhanced by increased 
prostaglandin levels, such as prostaglandin E1 and prostaglandin E2, both of which are 
enhanced by SCFA production (112).  Bacterial populations are surprisingly stable 
within individuals, supporting the notion that mechanisms may exist to promote the 
abundance of beneficial bacteria and suppress the growth of undesirable species (5, 113).   
 Many gastrointestinal organisms also contribute to the host defense by producing 
antibacterial peptides (e.g., bacteriocins) such as colicins and microcins (114).  
Antibacterial peptides are present on the cytoplasmic membranes of certain microbial 
species, and exert pathogen-lytic activities against pathobionts and pathogens (115).  In 
the wake of increasing antimicrobial resistance, it is suggested that antimicrobial 
peptides may have the potential to serve as the next generation of antibiotics (116). 
 
Failure of a Virtual Organ: Dysbiosis 
 While the benefits of a healthy gastrointestinal tract are numerous, negative shifts 
in the bacterial population can result in negative effects on the human host.  The theory 
of dysbiosis, originally coined to describe altered pathogenic bacteria in the gut, has 
been prevalent since the early twentieth century (117).  Dysbiosis has more recently 
been defined as qualitative and quantitative changes in the intestinal flora, their 
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metabolic activity and their local distribution (118).  It is hypothesized that various 
lifestyle factors, such as poor dietary intake (119), prolonged antibiotic use (120), or 
physical and psychological stress (121, 122), can all result in a negative alteration of 
bacterial populations. 
 It has been observed that when a diet high in food additives is regularly 
consumed, levels of potentially toxic bacteria products, such as endotoxins, hydrogen 
sulfide, phenols, ammonia, and indoles increase in the gastrointestinal tract (18, 119, 
123).  This increase in byproduct production is associated with decreased colonization of 
beneficial bacteria and a subsequent increase in pathobionts (124).  The potential for an 
antimicrobial agent to influence the gastrointestinal microbiota hinges upon numerous 
factors, such as quantity and length of administration, both of which dose-dependently 
increase dysbiosis (120).  The use of various antibiotics has been shown to decrease 
indigenous lactobacilli and bifidobacteria populations, which could allow pathobiont 
colonization to increase (124).  The selectiveness of an antibiotic will also profoundly 
affect its potency.  For example, antimicrobial agents active against both gram-positive 
and gram-negative organisms will have a much larger impact than agents selective for 
only gram-negative bacteria (125).  An increase in stress, both physical and 
psychological, has been shown to decrease immunoglobulin A (IgA) concentrations and 
increase norepinephrine concentrations as a result of sympathetic nervous system 
activation (121, 126).  It is hypothesized that decreased IgA secretions may allow for 
increased colonization of pathobionts and pathogenic bacteria, which would lead to a 
dysbiotic state (121). 
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 Microbial imbalances occurring within the body have been associated with 
increased gastrointestinal inflammation and chronic disease states, such as Crohns 
disease and ulcerative colitis (127).  The composition of fecal and mucosal flora is 
distinctly different between healthy subjects and patients with irritable bowel disease 
(IBD), with levels of Firmicutes and bacterial diversity decreasing in IBD patients (128).  
It has been observed that polymorphisms in mucosal toll-like receptors are associated 
with an increased risk of IBD in animal and human models (129).  A decrease in toll-like 
receptor function causes a decreased innate immune response, which has been associated 
with higher levels of pathobiont colonization (130). 
 As evidence of the role of dysbiosis in the development and perpetuation of 
chronic gastrointestinal disorders increases, new methods for the correction of microbial 
imbalances are being explored.  Alteration of dietary intake is a manageable means to 
combat dysbiosis.  By altering dietary intake to increase substrate availability for 
beneficial bacteria, it could be possible to promote their growth and subsequently 
decrease pathobiont colonization.  This occurrence has been coined the “prebiotic effect” 
(36, 131). 
 
Microbiota Modulation: The Prebiotic Concept 
 Diet influences human health both directly and indirectly, by affecting the 
composition and activity of gastrointestinal microbiota. Food choices have a direct 
impact on the modulation of various bodily functions, and a low-fat, nutrient-rich diet 
improves the capacity for reducing disease risk throughout life (132).  Dietary intake can 
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also greatly affect the activity and proliferation of native gastrointestinal species and gut 
integrity, therefore it is imperative that natural beneficial food sources be identified and 
consumed (133). When natural beneficial food sources are not regularly consumed due 
to unavailability or distaste, food manufacturers are able to fortify foods with health 
bioactive ingredients such as probiotics and prebiotics.  
 The promotion of favorable colonization can be achieved through several 
avenues, notably the consumption of pre- and probiotics.  Probiotics are defined as live 
microorganisms which when administered in adequate amounts confer a health benefit 
on the host (134). Probiotic consumption has been suggested to increase levels of 
desirable bacteria, which in some instances has been linked to improved gut 
functionality (42, 52, 135, 136).  Due to their transient colonization of the 
gastrointestinal tract, probiotics must be consumed regularly to maintain host benefit 
(133). The topic of probiotics, while important, is beyond the scope of this review.    
 Prebiotics are functional foods defined as a selectively fermented ingredient that 
allows specific changes, both in the composition and activity in the gastrointestinal 
microbiota, that confers benefits upon host wellbeing and health (137). While also 
transient in nature, prebiotic dietary sources may be easier to utilize than their probiotic 
counterparts, as the viability of live cultures can be difficult to maintain when 
incorporated into food products, and their shelf life is often short (133, 137-140).  
Therefore, continued research is being conducted to identify dietary components that 
beneficially stimulate the host flora. 
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Carbohydrates: Fuel for Two 
 Carbohydrates, along with lipids and proteins, are organic compounds considered 
to be major macronutrients in the body.  Dietary carbohydrates are derived primarily 
from plant sources and are principally substrates for energy metabolism, though they 
also affect satiety, blood glucose regulation, and lipid metabolism (141, 142).  Primary 
classification of dietary carbohydrates is by molecular size, determined by not only 
degree of polymerization, but also by the types of linkages utilized (141).  Carbohydrates 
may be subdivided into three distinct classes based on polymerization: sugars (1-2 
degrees of polymerization), oligosaccharides (3-9 degrees of polymerization), and 
polysaccharides (≥ 10 degrees of polymerization) (141).   
While sugars encompass mono- and disaccharides, oligosaccharides may be sub-
classified as either α-glucans (primarily occurring from starch hydrolysis) or non α-
glucans (commonly sucrose joined to varying numbers of galactose molecules) (141).  
Polysaccharides may be classified as starch (α-1,4 and α-1,6 glucans) or non-starch 
polysaccharides, which are primarily non-α-glucan components of the plant cell wall, 
such as cellulose, hemicellulose and pectin (141).   
The most abundant form of dietary carbohydrate is glucose, which is a 
monosaccharide produced in plants through photosynthesis (32).  Other dietary 
monosaccharides include fructose, galactose, and ribose (142).  These carbohydrate 
building blocks can be chemically polymerized in a variety of conformations and 
degrees of polymerization, ultimately affecting their availability for digestion. 
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When discussing carbohydrates, it is easiest to subdivide them into two groups: 
digestible carbohydrates and nondigestible carbohydrates. 
 
Digestible Carbohydrates: Sugars and Starch 
 Sugar and most forms of starch are readily digestible in the small intestine of 
humans.  Simple sugar refers to mono- and disaccharides, while starch refers to the 
polysaccharide storage form of carbohydrate found in plants (142).   
 Starch is the primary energy source for many animals, including humans (143).  
While the majority of starch molecules are readily digested by the host, some starch is 
not digested in the small intestine and arrives in the large bowel intact (144).  This is 
termed “resistant starch”, and will be discussed at length.  Starch is packaged into 
granules, which can be fractioned into two components: amylose and amylopectin.  
Amylose is a linear molecule composed of D-glucose units linked by α-(1,4) glycosidic 
bonds (143).  While the molecular weight of amylose varies depending upon its source, 
on average it will contain between 500 and 600 glucose units (145).  Amylopectin is a 
highly-branched form of starch composed of D-glucose α-(1,4) chains (12-70 residues) 
linked occasionally by α-(1,6) bonds (143).  It is considered a large molecule, with a 
molecular weight surpassing 107 Daltons, and is the major component of most starch 
granules (143, 145).  Most common cereal starches contain approximately 15% to 30% 
amylose (141).  As the level of amylose in a starch increases, its digestibility in the 
human gastrointestinal tract tends to decrease (141). 
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Roughly half of the typical western-style diet is composed of carbohydrates, 
especially sucrose and starch (38).  During digestion, various amylase enzymes 
hydrolyze the starch granules, liberating glucose molecules for absorption (143).  Once 
absorbed by the epithelial cells and transported to the blood, glucose will be transported 
to the liver and tissues for entry into various metabolic pathways (142).  Due to the high 
bioavailability (i.e., the degree to which an absorbed nutrient is available to the body) of 
sugars and most starches, very little reaches the large intestine for fermentation and short 
chain fatty acid production.  It has been estimated that less than 10% of digestible starch 
reaches the adult colon, mostly as a result of physical inaccessibility in the small bowel 
(38, 146).  Factors affecting the amount of starch reaching the ileum also include transit 
time, amylose concentration, and the presence of other food components (143).   
 
Indigestible Carbohydrates: Fiber and Resistant Starch 
 While physically inaccessible to the host, evidence supporting the benefits of 
indigestible carbohydrates on gastrointestinal health is mounting.  The primary form of 
indigestible carbohydrates is fiber, which are plant polysaccharides and lignin that are 
resistant to human digestive enzymes (147).  The definition of fiber continues to evolve.  
In 2001, the Institute of Medicine formed a panel of researchers to develop the following 
definition: Total fiber is the sum of dietary fiber and functional fiber.  Dietary fiber 
consists of nondigestible carbohydrates and lignin that are intrinsic and intact in plants.  
Functional fiber consists of isolated, nondigestible carbohydrates that have beneficial 
physiological effects in humans (148).  The debate on whether or not resistant starch 
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should be categorized as a fiber is ongoing.  While resistant starch may share some of 
the physiological effects and health benefits of fiber, it is still unclear if it should be 
considered part of dietary fiber (149, 150).  Fiber and resistant starch will be discussed 
separately.   
 Fiber is composed primarily of non-starch polysaccharides (NSP) such as 
cellulose, hemicellulose, and pectin, though many oligosaccharides also fall into this 
category (151).  The solubility of each fiber source directly determines its function in the 
gastrointestinal tract.  Insoluble fibers, such as lignin, cellulose, and some forms of 
hemicellulose, resist fermentation by colonic microbiota (146).  As they pass through the 
gastrointestinal tract undigested, insoluble fibers play a significant role in fecal bulking, 
aiding in the movement of fermentable carbohydrates into the large intestine (146).  In 
contrast, soluble fibers such as pectin, gum, mucilage, and some hemicellulose, are 
almost entirely fermented by gastrointestinal bacteria.  Decreased fecal bulking is 
contributed to high soluble fiber consumption, and can be associated with delayed 
gastric emptying and increased bowel transit time when compared to insoluble fiber (34, 
38).  While transit time may be decreased, soluble fiber is a good substrate for short 
chain fatty acid production, which is ultimately beneficial to gut health (38).  
   Non-starch polysaccharides are the principle substrate for microbial short chain 
fatty acid production.  Resistant starch garnered very little attention in dietetics until 
studies showed that NSP intake alone could not account for the total bacterial cell 
turnover and SCFA production, suggesting that there was an unidentified „carbohydrate 
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gap‟ (43, 152).  While this gap is partially filled by oligosaccharide metabolism, the 
primary contributor to this deficit is believed to be resistant starch (36). 
 The typical western diet contains between 1 and 5 grams of resistant starch per 
day, and can be found in a variety of sources such as green bananas, raw potatoes, 
certain legumes, high-amylose starches, and chemically modified starch used in 
processed foods (133).  Resistant starch is currently subdivided into five categories: 
physically inaccessible (RS1), raw (RS2), retrograded starch (RS3), chemically modified 
(RS4), and v-form (RS5) (133).   
 
Physically inaccessible starch (RS1).  RS1 is commonly found in whole or 
partially milled grains.  It is generally composed of starch granules that are 
surrounded by other insoluble plant materials, which inhibit proteases and 
amylases from degrading it.  Food particle size is also a factor in starch 
availability, as larger particles are better able to encase granules, limiting enzyme 
access (143). 
  
Raw starch (RS2). RS2 is commonly found in high-amylose starches, along with 
certain leguminous starches.  Examples of these foods include raw potatoes, 
green bananas, and leguminous peas (133).  RS2 occurs with no outside 
modifications, and can be consumed regularly as a dietary source of resistant 
starch.  While naturally found in the diet, several studies have demonstrated that 
RS2 is poorly utilized by bacteria in the large intestine (153-155). 
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Retrograded starch (RS3).  Retrogradation is the process of suspending starch in 
water and heating at high temperatures, followed by a slow cooling period (156).  
The result of retrogradation is the formation of cross-links (i.e., hydrogen 
bonding of hydroxyl groups on adjacent chains) between the long amylose 
chains, increasing the stability of the molecule by creating bonds resistant to 
amylase activity.   Due to its compact, unbranched nature, RS3 is very resistant 
to amylolytic digestion (157).   Retrogradation of resistant starch is highly 
dependent upon chain length (158).  RS3 is commonly found in starch-containing 
foods that have been cooked and slowly cooled, such as potato salad. 
 
Chemically modified starch (RS4). Chemically modified resistant starch is 
produced through the etherization, esterification, or cross-bonding (i.e., the 
covalent or ionic bonding of  D-glucose chains) of starches (133).  RS4 is often 
used as a food additive to increase levels of dietary resistant starch.  RS4 may 
also resist digestion in the large intestine.  One study found that when a rat model 
consumed RS4, roughly 50% was excreted in the feces undigested (159).   
 
V-form starch (RS5). Resistant starch may potentially be classified as v-form, 
which refers to amylose that has interacted with polar lipids to form 
semicrystalline structures highly resistant to hydrolysis (133).  V-forms can be 
produced from mono- and diglycerides, as well as saturated and unsaturated fatty 
acids (160).  These amylase-lipid complexes have high melting temperatures and 
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decreased digestibility due to their complex formation (160).  Modification of 
food texture and stability via the integration of RS5 has been a focus in the food 
science industry (161). 
 
 Resistant starch has been proven effective in lowering blood glucose levels.  In 
one instance, a 62% amylose resistant starch diet decreased plasma glucose levels 
compared to a highly digestible starch control (162).  High amylose maize starch diets 
were also shown to decrease plasma glucose by lowering the digestible starch content 
available in the gastrointestinal tract (163).  Both RS2 and RS3 fail to act as a reservoir 
for prolonged release of glucose.  These studies show that any available starch in the diet 
was rapidly digested, and the resistant starch in the diet entered the colon (150).  While 
resistant starch consumption will not counteract the digestion of starch already present in 
the diet, these studies suggest that using resistant starch as a replacement for digestible 
starches may be beneficial to populations suffering from hyperglycemia. 
 While technically a starch, resistant starch behaves much like non-starch 
polysaccharides, increasing colonic fermentation and short chain fatty acid 
concentrations through the stimulation of beneficial bacterial populations (43).  The 
majority of in vivo studies have focused on the ability of RS2 and RS3 to positively 
affect bacterial growth.  The consumption of retrograded chickpea (Cicer arietinum L.) 
and pea cultivar (Pisum sativum, L.) by 21 to 23-day old male Wistar rats over a 28-day 
period both showed a significant increase in cecal bifidobacteria (164).  The zero time 
counts for Bifidobacterium were 6.5  0.3 log10 (colony forming units/gram raw 
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material).  At day 28, Bifidobacterium were significantly higher during both chickpea (p 
< 0.05) and pea cultivar (p < 0.01) consumption, with final counts of ~8.0 log10 (colony 
forming units/g raw material) and ~9.5 log10 (colony forming units/g raw material), 
respectively [precise enumeration not provided] (164).  Consumption of modified 
retrograded potato starch by 56-day old rats exhibited no significant increase in 
bifidobacteria population (p > 0.05) (164).   
Consumption of commercial RS3 products has also resulted in increased cecal 
bifidobacteria.  CrystaLean (SunOpta, Inc.), a retrograded amylose starch consumed by 
human flora-associated (HFA) Fisher rats over a 28-day period, caused a 100-fold 
increase in the cecal bifidobacteria (p < 0.001) of Italian-HFA rats, with a final 
bifidobacteria count of 8.69  0.52 log10 (colony forming units/g raw material) compared 
to a sucrose control (165).  Bifidobacteria concentrations also significantly increased (p 
< 0.01) in United Kingdom-HFA rats, with a final bifidobacteria count of 7.91 log10 
(colony forming units/g raw material).  Lactobacilli populations were also significantly 
increased (p < 0.001) in Italian and United Kingdom-HFA rats, with final bifidobacteria 
counts of 7.69 log10 (colony forming units/g raw material) and 7.89 log10 (colony 
forming units/g raw material), respectively (165). 
Novelose 330 (National Starch and Chemical, Hamburg, Germany), an RS3 
commercial grade resistant starch, also caused a significant increase (p < 0.001) in 
bifidobacteria populations compared to a wheat starch control when fed in conjunction 
with oat bran to young male Wistar rats over a 42-day period (166).  Final bifidobacteria 
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counts after day 42 were approximately 9.2 log10 (colony forming units/g feces).  No 
significant increase was observed in lactobacilli populations (p > 0.05) (166).   
Novelose 260 (National Starch and Chemical, Hamburg, Germany), a similar 
RS3 commercial grade resistant starch, caused significant increases (p < 0.05) in 
bifidobacteria and lactobacilli populations of four-week old male Sprague-Dawley rats 
over a 6-week period compared to a cellulose control (167).  At day 42 of consumption, 
bifidobacteria counts were 9.4 log10 (colony forming units/g cecal contents) in diets 
prepared with Sunola oil, and 8.7 log10 (colony forming units/g cecal contents) when 
diets were prepared with fish oil.  Lactobacilli counts were 8.9 log10 (colony forming 
units/g cecal contents), regardless of oil used during diet preparation (167). 
 Raw resistant starch (RS2) has also shown the ability to positively effect 
bifidobacteria and lactobacilli proliferation.  High amylose maize starch (Starch 
Australia, Lane Cove, Australia) has been shown to beneficially stimulate lactobacilli 
and bifidobacteria populations compared to a Mazaca 3401x cornstarch control in a 
porcine model after 21 days of consumption, both before and after hydrothermal 
treatment of the resistant starch (168).  When digesta was analyzed, high amylose maize 
starch caused significant increases in lactobacilli (p < 0.05) and bifidobacteria (p < 0.01) 
compared to the control, with final counts of 7.5 log10 (colony forming units/g digesta) 
and 8.12 log10 (colony forming units/g digesta), respectively.  After hydrothermal 
treatment of high amylose maize starch, lactobacilli (p < 0.05) and bifidobacteria (p < 
0.01) populations were also significantly higher than the control, with final counts of 7.7 
log10 (colony forming units/g digesta) and 8.12 log10 (colony forming units/g digesta), 
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respectively.  When fecal samples were analyzed after high amylose maize consumption, 
levels of lactobacilli (p < 0.01) and bifidobacteria (p < 0.01) were once again 
significantly higher than consumption of the control diet, with final counts of 7.96 log10 
(colony forming units/g feces) and 8.45 log10 (colony forming units/g feces), 
respectively.  Consumption of hydrothermal-treated high amylose maize starch caused 
decreases in lactobacilli (7.52 log10 (colony forming units/g feces)) and bifidobacteria 
(7.89 log10 (colony forming units/g digesta)) counts in comparison to untreated high 
amylose maize starch, though both significantly increased in comparison to the control 
(p < 0.05) (167). 
A similar porcine study utilizing White strain 14-week old male pigs did not 
result in an increase in bifidobacteria proliferation (4 colony forming units/g feces 
detection limit) when high amylose maize starch was provided, but an increase in fecal 
bulk was noted (169).  Yet in the same study, supplementation of an oral B. longum 
prebiotic in conjunction with high amylose maize starch resulted in significantly higher 
levels of bifidobacteria in comparison to a low amylose control (p < 0.01), with a fecal 
concentration of 8.91 log10 (colony forming units/g wet weight) (169).   
Rat models examining RS2 consumption have exhibited varying effects on 
bacterial proliferation.  Consumption of native granular potato starch (Emsland Stärke 
Gmbtl, Emlichheim, Germany) containing approximately 60% (w/w) resistant starch by 
8-week old Wistar rats resulted in no significant increase in bifidobacteria and 
lactobacilli populations in comparison to a waxy maize starch control (p > 0.05) (170). 
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Consumption of an RS2 high amylose maize starch (HiMaize™ Starch Australia) 
by 4-week old Sprague-Dawley rats resulted in significant increases of both 
bifidobacteria (p < 0.05) and lactobacilli (p < 0.05) after six weeks of consumption 
(167).  When the diet was prepared using Sunola oil, lactobacilli counts were 8.7 log10 
(colony forming units/g cecal contents) and bifidobacteria counts were 9.2 log10 (colony 
forming units/g cecal contents).  When the high amylose maize starch diet was prepared 
with fish oil, lactobacilli counts did not change, though bifidobacteria counts decreased 
to 8.9 log10 (colony forming units/g cecal contents) (170).  Table 2 provides an outline of 
various in vivo studies examining the ability of various resistant starches to stimulate 
bacterial proliferation. 
By increasing short chain fatty acid production via resistant starch consumption, 
the pH of the gastrointestinal tract is decreased.  A low pH has been shown to decrease 
the conversion of primary bile acids to secondary bile acids, which has been associated 
with the promotion of apoptosis-resistant epithelial cell differentiation (171).  With 
scientific evidence showing increased fermentation of a resistant starch diet, short chain 
fatty acid production during resistant starch consumption has also been observed.  
Sprague-Dawley rats fed a diet high in 48% amylose resistant starch as a component of 
25% whey (1166 μmol) or 25% soya diets (1020 μmol) displayed increased total large 
bowel short chain fatty acid concentrations when compared to control rats consuming 
similar diets containing highly digestible corn starch (p < 0.05) (172).  Consumption of 
the resistant starch diet decreased DNA damage (p < 0.05) and mucosal barrier damage 
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(p < 0.05) associated with high protein consumption, suggesting that resistant starch may 
be helpful in maintaining gut integrity (172).   
 While resistant starch has been used in food manufacturing to improve the 
functional characteristics of processed foods, little has been done in recent years to 
advance its classification as a prebiotic The aforementioned studies indicate that 
consumption of diet high in resistant starch beneficially stimulates the proliferation of 
beneficial bacteria, which supports the claim that resistant starch may be used as a 
prebiotic supplement.   
While research is promising, it is difficult to directly link resistant starch 
consumption directly to prebiotic action.  There is little information on the daily resistant 
starch consumption patterns in humans, as well as a lack in validated analytical methods 
for determining resistant starch levels in food products (133).  While studies demonstrate 
the benefits of resistant starch at high concentrations, it is highly doubtful that such 
levels of resistant starch will be consumed on a daily basis.  The average adult on a 
western-style diet consumes 1 to 5 grams of resistant starch per day (133).  If this 
statistic were applied to a 150-pound (68 kilogram) human, this would equate to 68-340 
g/kg resistant starch consumption per day.  Many resistant starch studies provide 400-
600 g/kg of resistant starch to subjects, which far exceeds average daily intake (168, 170, 
173).  In order to classify resistant starch as a viable prebiotic, additional research must 
be conducted to determine a means for its quantification in food sources, as well as 
determine its utilization throughout the gastrointestinal tract.  The level of resistant 
starch provided in experimental diets should also be comparable to human intake, 
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allowing for the data collected to be accurately applied to the general public.  Once 
viable prebiotics are identified, this knowledge can hopefully be utilized to improve the 
dysbiotic state prevalent in many gastrointestinal disorders, improving the health and 
wellbeing of a large subset of the population. 
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CHAPTER III 
 
EFFECTS OF RESISTANT STARCH AND SOLUBLE CORN FIBER DIETS ON 
THE PROLIFERATION OF BIFIDOBACTERIA AND LACTOBACILLI  
IN VIVO 
 
 
Introduction 
 
The human gastrointestinal tract is host to a large, complex and dynamic 
microbial community (174).  With only 400 of the estimated 1000 bacterial species 
cultivated and characterized from the human gastrointestinal tract, the full effect of 
microbial colonization on the human host has not been full explored (175).  While many 
extrinsic factors may influence microbial colonization, diet is a major and dynamic 
niche-determining variable that preferentially shapes the relative taxonomic and 
metabolic diversity of constituent microorganisms (174).  Even from birth, consumption 
of human breast milk has been shown to directly stimulate the growth of certain bacterial 
species, most notably bifidobacteria (176).  Through competitive exclusion, the growth 
of certain bacteria is enriched, while simultaneously selecting against others (140).  By 
hydrolyzing and fermenting certain dietary constituents, bacteria can proliferate at a 
rapid rate.  Implementing changes in diet can alter the species composition of the 
microbiota, as well as alter many physiological traits (e.g., enzyme activity) (131).  
Furthermore, in the case of secondary fermenters (i.e., bacteria that utilize fermentation 
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products released from other species), diet is an intermediary factor influencing their 
microbial proliferation (174). 
  Dietary fiber can preferentially stimulate bacterial proliferation.  Total fiber has 
been defined as consisting of two distinct parts: dietary fiber and functional fiber.  
Dietary fiber consists of nondigestible carbohydrates and lignin that are intrinsic and 
intact in plants, while functional fiber consists of isolated, nondigestible carbohydrates 
that have beneficial physiologic effects in humans (148).  Fiber is composed primarily of 
non-starch polysaccharides (NSPs), which cannot be enzymatically degraded in the 
upper gastrointestinal tract.  Therefore, they remain relatively intact when they reach the 
colon, where large and metabolically diverse populations of microorganisms, including 
beneficial bifidobacteria, actively hydrolyze and catabolize these molecules, producing 
metabolic endproducts such as short chain fatty acids (SCFA) (36).  As a result of these 
activities, the proliferation and/or activity of select gastrointestinal microorganisms is 
stimulated through the so-called prebiotic effect (36, 131).  Prebiotics are selectively 
fermented ingredient that allows specific changes, both in the composition and/or 
activity in the gastrointestinal microbiota that confers benefits upon host wellbeing and 
health (137). 
  Resistant starch and non-starch polysaccharides (NSPs) are the principal 
substrates for microbial SCFA production, which primarily include acetate, propionate, 
and butyrate (36).  Short chain fatty acids play an integral role in maintaining large 
bowel function, and are believed to prevent pathology through their metabolism in 
colonocytes.  While microbial NSP metabolism does contribute to SCFA production, 
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they do not fully account for total human SCFA production.  This “carbohydrate gap” is 
partially filled by oligosaccharide metabolism, but the primary contributor to this deficit 
is believed to be resistant starch (36).  Resistant Starch is defined as the sum of starch 
and products of starch degradation not absorbed in the small intestine of healthy 
individuals (144).  While technically a starch, resistant starch behaves similarly to NSPs, 
entering the large bowel undigested and increasing colonic fermentation and SCFA 
concentrations (43), which has spurred many researchers to examine its prebiotic 
potential. 
 Resistant starch has shown prebiotic potential both in vivo and in vitro (36, 165, 
169, 170, 177, 178).  While resistant starch has been used by food manufacturers to 
improve the functional characteristics of processed foods, little has been done in recent 
years to advance its classification as a prebiotic (36).  The objective of our study was to 
determine the ability of a resistant starch diet, in conjunction with two fermentable 
polysaccharide diets, to selectively stimulate the growth of beneficial microorganisms, 
specifically bifidobacteria and lactobacilli, in the gastrointestinal tract of rats.   
 
Materials and Methods 
 
Bacterial Strains and Cultivation Conditions 
Standard curves for lactobacilli and bifidobacteria analysis were prepared as 
follows: Lactobacilli acidophilus ATCC 4356 (American Type Culture Collection) and 
Bifidobacterium adolescentis ATCC 15703 were cultivated in MRS broth (Becton 
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Dickinson) and incubated in an anaerobic chamber (Coy Laboratory Products) at 37°C 
for 24 hours (Table 3). 
 
Study Design and Fecal Collection 
A total of 120, 7-week old, male Sprague-Dawley rats (Harlan Laboratories) 
were individually housed in a temperature and humidity controlled facility.  The animal 
use protocol was approved by the University Laboratory Animal Care Committee of 
Texas A&M University (College Station, TX) and conformed to National Institutes of 
Health guidelines.  The environment was held at 20-22C.  Rats were adapted to a 12-
hour light/dark cycle throughout the experimental period. 
 Rats were staggered in four sets to allow adequate time to sacrifice and harvest 
tissues for downstream analysis.  Rats were allowed to consume water and a chow diet 
(Harlan) ad libitum for a minimum of three days prior to adaptation to one of four 
experimental diets ad libitum.  Experimental diets consisted of a corn oil base 
supplemented with either: 6% (w/w) cellulose (Bioserv, Frenchtown, NJ) (C diet); 2% 
(w/w) cellulose combined with 4% (w/w) PROMITOR soluble corn fiber (Tate & 
Lyle, Decatur, IL) (S diet); 2% cellulose combined with 4% (w/w) PROMITOR 
resistant starch (Tate & Lyle, Decatur, IL) (R diet); or a 1:1 mixture of PROMITOR 
soluble corn fiber and PROMITOR resistant starch diets (M diet) (Table 4).  Unless 
otherwise indicated, all base components were purchased from Research Diets.  
Polysaccharide additives were combined with following ingredients (w/w): 51.06% 
dextrose, 22.35% casein, 0.34% DL-methionine, 3.91% mineral mix, 1.12% vitamin mix, 
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0.22% choline bitartrate, and 15.00% corn oil (Dyet, Inc.) (Table 5).  The soluble corn 
fiber had a degree of polymerization (DP) of 10, with an average molecular weight of 
1640 Daltons (179).  It is highly branched, with predominately -1,4-glycosidic 
linkages.  The resistant starch was retrograded (RS3) (179).  It had an average molecular 
weight of 4000 Daltons, and a DP of 25.  Molecules are linear, utilizing -1,4-glcosidic 
linkages (179). 
Diets were consumed for two weeks before rats consuming experimental diets 
were challenged with 3% DSS in water for 48 hours, followed by a 14-day recovery 
period and a second 48-hour DSS challenge.  Ten rats consuming each diet did not 
receive DSS and served as a control group.  Fecal samples were collected weekly, and 
thirty control rats not receiving DSS treatment were selected for analysis.  Ten days after 
the last DSS treatment, rats were terminated using CO2 asphyxiation, followed by 
cervical dislocation.   
Fecal samples (Figure 1) were collected from individual rats at 3-hour increments 
during the dark cycle over a 12-hour period spanning the hours of 7 p.m. to 7 a.m.  
Samples were stored by time point in 2mL microtubes and immediately frozen at -80°C.  
Prior to processing, one fecal pellet from each 3-hour timepoint of the collection period 
was combined in a clean 2mL microtube to produce a representative sample of fecal 
movements over the 12-hour period.  Representative samples were prepared per rat for 
each collection date and frozen at -80°C until processing. 
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DNA Extraction  
Figure 2 provides a simple illustration of the processing and quantitative analysis 
steps.    Fecal samples were weighed in 15mL plastic tubes and combined with 5mL of 
10mM tris(hydroxymethyl)aminomethane (Tris) HCl buffer, (pH= 8.0).  Samples were 
homogenized using a FastPrep (MP Biomedicals) for 2 minutes at 4.0 m/s.  500mL of 
the resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for 
Soil (MP Biomedicals) following manufacturer‟s directions.  DNA concentration was 
determined using spectrophotometry (Nanodrop).  Purified DNA was stored at -20C 
prior to analysis. 
 
Quantitative Real Time qPCR 
 Real-time qPCR was used to determine the number of lactobacilli and 
bifidobacteria in fecal homogenates.  The oligonucleotide primers (Integrated DNA 
Technologies) used in this study to enumerate Bifidobacterium spp. (77) and the 
Lactobacillus-group (88) are described in Table 6.  
 Each quantitative PCR reaction (25L) contained 12.5L 2 B-R SYBRgreen 
supermix (VWR), 1L of each 25M oligonucleotide primer, 9.5L sterile deionized 
water, and 1L template.  For lactobacilli, 5ng/L template was included in each qPCR 
reaction regardless of diet. For bifidobacteria, template concentrations varied depending 
upon diet consumed to ensure that sample measurements were taken within the linear 
range of the standard curve: 5ng/L template was included for qPCR reactions from rats 
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consuming the M or R diet, while 50ng/L template was included from rats consuming 
the S or C diets.  
For each primer set, standard curves were used to determine the number of 
Lactobacillus-group and Bifidobacterium spp. 16S rRNA gene copies/g per gram of 
feces.  Lactobacillus acidophilus ATCC 4356 and Bifidobacterium adolescentis ATCC 
15703 were cultivated overnight for the creation of two separate standard curves.   
Cellular homogenization was performed using the FastPrep-24 (MP Biomedicals) for 40 
seconds at 6.0 m/s, and DNA was extracted using the FAST DNA Spin for Soil Kit (MP 
Biomedicals). In order to obtain a template concentration dose-response curve, these 
templates were serially decimally diluted to the final initial DNA concentrations noted in 
Table 7.   
In order to account for PCR inhibitors found in feces, DNase-treated autoclaved 
feces extract (DAFE) was also added to the standard curve.  Homogenized feces were 
autoclaved at 121C, and then DNA was extracted using the FAST DNA Spin for Soil 
Kit (MP Biomedicals).  Following spectrophotometry (Nanodrop), DNA was treated 
with 1L of DNase I (Invitrogen) for every 50L present for 60 minutes to remove 
remaining DNA.  DNase I was deactivated by heating samples in a water bath at 96C 
for 1 hour.  The solution was then diluted in accordance to the initial spectrophotometry 
results. A negative template control was also included to determine the lower limit of 
detection. 
Reactions were carried out in an iQ5 thermocycler (Bio-Rad).  For lactobacilli, 
reactions were cycled as follows: 95C for 3 minutes, followed by 45 cycles of 95C for 
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15 seconds, and 60C for 45 seconds (88). For bifidobacteria, reactions were cycled 
94C for 5 minutes, 40 cycles of 94C for 20 seconds, 55C for 20 seconds, and 72C 
for 50 seconds (77).  This was followed by an additional 94C for 15 seconds.  A melt 
curve was used following the completion of the thermal cycling programs to determine 
the specificity of the PCR.  The melting curves were obtained by slow heating at 
0.5C/30s increments from 55C to 95C, with continuous fluorescence collection.   
 
Data Analysis 
All real time qPCR samples were processed in triplicate, with triplicate positive 
and negative (template-free) controls on each plate.  Data was analyzed using Bio-Rad 
iQ5 2.0 Standard Edition software.  Copy numbers for each sample were standardized 
per gram of feces utilized for DNA extraction (16S rRNA gene copies/g feces).  
Statistical analysis was completed using SPSS 15.0 for Windows. A p value less than or 
equal to 0.05 was considered statistically significant. 
 
Results 
 
Characteristics of Fecal Pellets Vary in Relation to Diet Consumed 
 Throughout the course of the study, it was observed that fecal pellet belonging to 
rats consuming the R diet were consistently larger than pellets of rats consuming the S 
and M diets. Rats consuming the C diet consistently produced fecal pellets similar in size 
and shape to those of rats consuming the R diet.  
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Real Time PCR Detection of Bifidobacteria and Lactobacilli 
Standard curves composed of serially diluted (106 to 0 cells) DNA extracted from 
B. adolescentis ATCC 15703 and DAFE components were included on every plate, with 
fluorescence monitoring throughout the reaction.  As a result, the number of starting 
cells and the cycle number indicating greatest product fluorescence were linear over the 
range of DNA concentrations (R2 = 0.934  0.049).  Standard curves were also generated 
for lactobacilli as described above, except DNA was extracted from L. acidophilus 
ATCC 4356.  The number of starting cells and the cycle number indicating greatest 
product fluorescence were also linear (R2 = 0.972  0.021). A representative regression 
curve from Lactobacillus acidophilus is shown in Figure 3.  
 
Dietary Effects on Fecal Levels of DNA 
The amount of DNA extracted from one gram of feces per day of study for rats 
consuming each experimental diet is displayed in Figures 4-7.  Over the course of the 
study, consumption of the R diet resulted in a nonsignificant decrease in nanograms 
DNA per gram feces (p = 0.250) (Table 8), from 1.10105 ng DNA at day 1 of study to 
9.28104 ng DNA at day 43 (Figure 8). Consumption of the C diet also caused a 
nonsignificant decrease in DNA per gram feces (p = 0.485), from 1.34105 ng DNA at 
day 1 to 1.19105 ng DNA at day 43 (Figure 8). Rats consuming the M diet (p = 0.250) 
and S diet (p = 0.833) did see increases in DNA levels per gram feces over time, though 
both were nonsignificant (Figure 8). Consumption of the M diet caused a 1.299-fold 
increase in DNA per gram feces, increasing from 1.31105 ng DNA at day 1 of study to 
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1.69105 ng DNA at day 43 of study (Table 8). Consuming the S diet caused a 1.12-fold 
increase in DNA per gram feces over time, increasing from 1.29105 ng DNA at day 1 to 
1.45105 ng DNA at day 43 (Table 8). 
While the amount of DNA extracted from the feces of rats consuming each 
experimental diet was examined (Figures 4-7), the feces of rats treated with DSS were 
also analyzed to determine if diet had an effect on levels of DNA present (Figures 9-12).  
Over the course of the study, consumption of the R diet resulted in elevated levels of 
DNA in feces (from 1.37104 ng/g on day 1 to 1.78104 ng/g on day 43) but these were 
nonsignificant, (p = 0.560) (Table 9). Consumption of the C diet caused a nonsignificant 
decrease in DNA per gram feces (p = 0.514), from 1.12104 ng DNA at day 1 to 
9.29103 ng DNA at day 43 (Figure 13). Rats consuming the M diet (p = 0.207) and S 
diet (p = 0.125) did see increases in DNA levels per gram feces over time, though both 
were nonsignificant (Table 9). Consumption of the M diet caused a 2.50-fold increase in 
DNA per gram feces, increasing from 7.37103 ng DNA at day 1 of study to 1.84104 
ng DNA at day 43 of study (Table 9). Consuming the S diet caused a 1.39-fold increase 
in DNA per gram feces over time, increasing from 1.28104 ng DNA at day 1 to 
1.77104 ng DNA at day 43 (Table 9).  
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Dietary Effects on Proliferation of Bifidobacteria  
 Upon receipt, individually housed animals were initially fed a standard chow diet 
for a period of three days.  Animals were then transitioned to one of four experimental 
diets.  Fresh fecal samples were collected weekly and the number of fecal lactobacilli 
and bifidobacteria were determined as a function of time. 
  Initial bifidobacteria levels when consuming chow diet (prior to introduction of 
the resistant starch diet) were 2.17107 16S rRNA gene copies/g feces, yet after 43 days 
consuming the experimental diet, 5.75108 16S rRNA gene copies/g feces were 
observed (Figure 14).  A washout period was not experienced by rat consuming the R 
diet, as bifidobacteria populations were consistently higher than those witnessed during 
chow consumption for the duration of the study. At day 43 of the study, consumption of 
a resistant starch diet caused a 26.54-fold increase in bifidobacteria 16S rRNA gene 
copies/g feces in comparison to bifidobacteria during chow consumption (p = 0.000) 
(Table 10).  The number of bifidobacteria peaked during day 36 of the study, as the 
resistant starch diet caused a 101-fold increase in bifidobacteria levels in comparison to 
the cellulose control diet (p = 0.000) (Figure 14). 
 During consumption of the chow diet, initial bifidobacteria levels of rats assigned 
to the S diet were 2.66108 16S rRNA gene copies/g feces.  The soluble corn fiber diet 
caused no significant increase (-0.013 fold change) in bifidobacteria by day 43 (p = 
0.114), with a final population of 3.32106 16S rRNA gene copies/g feces (Table 10) 
(Figure 14).  Bifidobacteria populations during soluble corn fiber diet consumption were 
lowest on day 35, when 3.02103 16S rRNA gene copies/g feces were observed. 
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Populations were highest during chow diet consumption, as rats consuming the S diet 
experienced a washout of bacteria after introduction of the experimental diet. 
 Consumption of the M diet did cause a 9.61-fold increase in bifidobacteria from 
day 1 to day 43 of the study (p = 0.009). During chow consumption, 1.69107 16S rRNA 
gene copies/g feces of bifidobacteria were observed, while numbers increased to 
1.63108 16S rRNA gene copies/g feces by day 43 (Table 10). Rats consuming the M 
diet also experienced a washout after introduction of the experimental diet, with 
bifidobacteria levels lowest at day 7 of the study (4.11106 16S rRNA gene copies/g 
feces), although by day 29 of M diet consumption, bifidobacteria levels peaked at 
2.97108 16S rRNA gene copies/g feces (Table 10).  Although the M diet contained 50% 
of the resistant starch contained by the R diet, there was not a linear effect (Figure 14).  
 The number of bifidobacteria increased 1.68-fold during consumption of the 
cellulose diet, increasing from 4.21106 16S rRNA gene copies/g feces during chow 
consumption to 7.06106 16S rRNA gene copies/g feces by day 43 of the study (Table 
10). Bifidobacteria populations were highest on day 36 of the study (6.3106 16S rRNA 
gene copies/g), yet experienced a sharp decline at day 39, falling to 2.41104 16S rRNA 
gene copies/g. Log transformation of the data is displayed in Figure 15.  
Boxplots of log 10 16S rRNA gene copies/g feces of bifidobacteria over time are 
represented for each diet in Figure 16. During consumption of the C diet, significant 
differences from day 1 were observed on day 28 (p = 0.026), day 36 (p = 0.027), day 37 
(p = 0.05), and day 43 (p = 0.001). Day 39 of C diet consumption caused a significant 
decrease in bifidobacteria in comparison to day 1 (p = 0.015). Apart from days 22 and 
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35, bifidobacteria levels were significantly different from baseline throughout the study 
(p < 0.05). Bifidobacteria levels were significantly lower than baseline only on day 7 (p 
= 0.000). R diet consumption caused significantly different bifidobacteria levels 
throughout the course of the study (p < 0.05). Day 22 (p = 0.001), day 35 (0.001), and 
day 36 (p = 0.001) of S diet consumption was found to be significantly different from 
day 1 (Figure 16). 
 
Dietary Effects on Proliferation of Lactobacilli 
 Consumption of the R diet caused no significant increase in lactobacilli from day 
1 to day 43 of the study (p = 0.628) (Figure 17).  While 1.371010 16S rRNA gene 
copies/g feces of lactobacilli were observed at day one, only 1.211010 16S rRNA gene 
copies/g feces were observed at the completion of the study (Table 11). Numbers of 
lactobacilli were lowest at day 7 of the study (7.31109 16S rRNA gene copies/g feces) 
after introduction of the experimental diet, and numbers peaked on day 30 of the study, 
with 1.481010 16S rRNA gene copies/g feces of lactobacilli observed. 
 Consumption of the S diet caused a significant decrease in lactobacilli levels 
from day 1 to day 43(p = 0.018) (Figure 17).  At day one, 2.761010 16S rRNA gene 
copies/g feces were observed, while only 2.26109 16S rRNA gene copies/g feces were 
noted at day 43 (Table 11). Lactobacilli were highest during consumption of the chow 
diet, yet reached their lowest point on day 35 of the study, with only 1.28108 16S rRNA 
gene copies/g feces observed. 
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 A significant decrease in lactobacilli was also observed during consumption of 
the M diet from day 1 to day 43 (p = 0.004) (Figure 17).  Day one lactobacilli levels 
were 5.14109 16S rRNA gene copies/g feces, dropping to 1.78108 16S rRNA gene 
copies/g feces at the end of the study. Lactobacilli numbers were lowest after 
introduction of the experimental diet, with only 9.25107 16S rRNA gene copies/g feces 
observed on day 7. Lactobacilli populations peaked at day 39 of the study (9.72109 16S 
rRNA gene copies/g feces). 
 Consumption of the cellulose diet also caused a decrease (p = 0.037) in 
lactobacilli levels, decreasing slightly from 1.861010 16S rRNA gene copies/g feces on 
day 1 of the study to 1.331010 16S rRNA gene copies/g feces on day 43 (Table 11).  
Lactobacilli levels are highest on day 1 and day 35 of the study, both of which exhibited 
1.861010 16S rRNA gene copies/g feces. A decline in lactobacilli was observed at day 
39 of the study, with the lowest level of lactobacilli observed (3.39109 16S rRNA gene 
copies/g feces).  No diet exhibited a significant increase in lactobacilli in comparison to 
the cellulose control throughout the duration of the study. Log transformation of this 
data displayed in Figure 18.  
Boxplots of log 10 16S rRNA gene copies/g feces over time are represented for 
each diet in Figure 19. During consumption of the C diet, significant differences (p < 
0.05) from day 1 were observed on each day of study, except for day 21 (p = 0.171) and 
day 35 (p = 0.154). Significant variation in lactobacilli levels were observed on day 7 (p 
= 0.000), day 14 (p = 0.043), day 29 (p = 0.001), day 30 (p = 0.001), day 35 (p = 
0.004), and day 43 (p = 0.004). Only day 22 of R diet consumption caused significantly 
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different lactobacilli levels throughout the course of the study (p = 0.025). Day 7 (p = 
0.018), day 14 (0.046), and day 36 (p = 0.002), day 37 (p = 0.000), day 39 (p = 0.014), 
and day 43 (p = 0.018) of S diet consumption was found to be significantly different 
from day 1. 
A separate statistical analysis of the data by Dr. Nikolay Bliznyuk utilizing a 
linear mixed model formulation to examine the effects of dietary consumption over a 50-
day period is included in appendix (Figures 20 & 21). 
 
Discussion   
 
 At the conclusion of this study, we found that consumption of a resistant starch 
diet caused a significant 26.54-fold increase in gastrointestinal bifidobacteria over time, 
while a soluble corn fiber diet did not (Figure 14). Consumption of a 1:1 mixture of 
resistant starch and soluble corn fiber caused a 9.61-fold increase in bifidobacteria over 
time, while consumption of the cellulose diet caused only a 1.68-fold increase in 
gastrointestinal bifidobacteria (Table 10). Resistant starch was unsuccessful in 
promoting lactobacilli populations when consumed over a 43-day period (Figure 17).  It 
is interesting to note that even during consumption of a cellulose diet, a small, yet 
significant increase in the bifidobacteria population was noted.  
 The resistant starch used in this study is retrograded (RS3).  Retrograded starch 
forms as a result of thermal processing in the presence of water, followed by a slow 
cooling process (180).  During heating, the crystalline structure of amylose and 
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amylopectin is disrupted, allowing the formation of a viscous solution.  When allowed to 
cool, linear molecules realign themselves using hydrogen bridges, forming a crystalline 
structure that is less available to enzymatic degradation (181).  The resistant starch used 
has an average molecular weight of 4000 Daltons, with a degree of polymerization of 25.  
Its starch molecules are linear, utilizing -1,4-glycosidic linkages (179). 
 Our results suggest that RS3 may be utilized as a prebiotic to stimulate the 
proliferation of bifidobacteria in vivo.  As previously discussed, resistant starch is 
believed to be effective in stimulating the proliferation of colonic bacteria, as has been 
shown in numerous in vivo studies utilizing plate count methods for bacterial analysis.  
When comparing real time qPCR results to plate count methods, the existence of various 
rrn operons in the genome must be taken into consideration.  16S rRNA sequences are 
highly conserved among bacterial groups, and there are multiple copies of the16S rRNA 
gene per chromosome (182).  Thus far, bifidobacteria and lactobacilli have been found to 
contain two to seven rrn operons (183).  With such variability in the number of 16S 
regions, the copy numbers calculated from real-time PCR can only be used as an 
estimation of true bacterial populations, and is most often slightly over-representative of 
bacterial populations (184). 
While technically a starch, resistant starch behaves much like non-starch 
polysaccharides, increasing colonic fermentation and short chain fatty acid 
concentrations through the stimulation of beneficial bacterial populations (43).  The 
majority of in vivo studies have focused on the ability of RS2 and RS3 to positively 
affect bacterial growth.  The consumption of retrograded chickpea (Cicer arietinum L.) 
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and pea cultivar (Pisum sativum, L.) by 21 to 23-day old male Wistar rats over a 28-day 
period both showed a significant increase in cecal bifidobacteria (164).  The zero time 
counts for Bifidobacterium were 6.5  0.3 log10 (colony forming units/g raw material).  
At day 28, Bifidobacterium were significantly higher during both chickpea (p < 0.05) 
and pea cultivar (p < 0.01) consumption, with final counts of ~8.0 log10 (colony forming 
units/g raw material) and ~9.5 log10 (colony forming units/g raw material), respectively 
[precise enumeration not provided] (164).  Consumption of modified retrograded potato 
starch by 56-day old rats exhibited no significant increase in bifidobacteria population (p 
> 0.05) (164).   
Consumption of commercial RS3 products has also resulted in increased cecal 
bifidobacteria.  CrystaLean (SunOpta, Inc.), a retrograded amylose starch consumed by 
human flora-associated (HFA) Fisher rats over a 28-day period, caused a 100-fold 
increase in cecal bifidobacteria (p < 0.001) in Italian-HFA rats, with a final 
bifidobacteria count of 8.69  0.52 log10 (CFU/g raw material) compared to a sucrose 
control (165).  Bifidobacteria concentrations also significantly increased (p < 0.01) in 
United Kingdom-HFA rats, with a final bifidobacteria count of 7.91 log10 (colony 
forming units/g raw material).  Lactobacilli populations were also significantly increased 
(p < 0.001) in Italian and United Kingdom-HFA rats, with final bifidobacteria counts of 
7.69 log10 (colony forming units/g raw material) and 7.89 log10 (colony forming units/g 
raw material), respectively (165). 
Novelose 330 (National Starch and Chemical, Hamburg, Germany), an RS3 
commercial grade resistant starch, also caused a significant increase (p < 0.001) in 
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bifidobacteria populations compared to a wheat starch control when fed in conjunction 
with oat bran to young male Wistar rats over a 42-day period (166).  Final bifidobacteria 
counts after day 42 were approximately 9.2 log10 (colony forming units/g feces).  No 
significant increase was observed in lactobacilli populations (p > 0.05) (166).   
Novelose 260 (National Starch and Chemical, Hamburg, Germany), a similar 
RS3 commercial grade resistant starch, caused significant increases (p < 0.05) in 
bifidobacteria and lactobacilli populations of four-week old male Sprague-Dawley rats 
over a 6-week period compared to a cellulose control (167).  At day 42 of consumption, 
bifidobacteria counts were 9.4 log10 (colony forming units/g cecal contents) in diets 
prepared with Sunola oil, and 8.7 log10 (colony forming units/g cecal contents) when 
diets were prepared with fish oil.  Lactobacilli counts were 8.9 log10 (colony forming 
units/g cecal contents), regardless of oil used during diet preparation (167). 
 Raw resistant starch (RS2) has also shown the ability to positively effect 
bifidobacteria and lactobacilli proliferation.  High amylose maize starch (Starch 
Australia, Lane Cove, Australia) has been shown to beneficially stimulate lactobacilli 
and bifidobacteria populations compared to a Mazaca 3401x cornstarch control in a 
porcine model after 21 days of consumption, both before and after hydrothermal 
treatment of the resistant starch (168).  When digesta were analyzed, high amylose maize 
starch caused significant increases in lactobacilli (p < 0.05) and bifidobacteria (p < 0.01) 
compared to the control, with final counts of 7.5 log10 (colony forming units/g digesta) 
and 8.12 log10 (colony forming units/g digesta), respectively.  After hydrothermal 
treatment of high amylose maize starch, lactobacilli (p < 0.05) and bifidobacteria (p < 
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0.01) populations were also significantly higher than the control, with final counts of 7.7 
log10 (colony forming units/g digesta) and 8.12 log10 (colony forming units/g digesta), 
respectively.  When fecal samples were analyzed after high amylose maize consumption, 
levels of lactobacilli (p < 0.01) and bifidobacteria (p < 0.01) were once again 
significantly higher than consumption of the control diet, with final counts of 7.96 log10 
(colony forming units/g feces) and 8.45 log10 (colony forming units/g feces), 
respectively.  Consumption of hydrothermal-treated high amylose maize starch caused 
decreases in lactobacilli (7.52 log10 (colony forming units/g feces)) and bifidobacteria 
(7.89 log10 (colony forming units/g digesta)) counts in comparison to untreated high 
amylose maize starch, though both significantly increased in comparison to the control 
(p < 0.05) (167). 
A similar porcine study utilizing White strain 14-week old male pigs did not 
result in an increase in bifidobacteria proliferation (4 colony forming units/g feces 
detection limit) when high amylose maize starch was provided, but an increase in fecal 
bulk was noted (169).  Yet in the same study, supplementation of an oral B. longum 
prebiotic in conjunction with high amylose maize starch resulted in significantly higher 
levels of bifidobacteria in comparison to a low amylose control (p < 0.01), with a fecal 
concentration of 8.91 log10 (colony forming units/g wet weight) (169).   
Rat models examining RS2 consumption have exhibited varying effects on 
bacterial proliferation.  Consumption of native granular potato starch (Emsland Stärke 
Gmbtl, Emlichheim, Germany) containing approximately 60% (w/w) resistant starch by 
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8-week old Wistar rats resulted in no significant increase in bifidobacteria and 
lactobacilli populations in comparison to a waxy maize starch control (p > 0.05) (170). 
Consumption of an RS2 high amylose maize starch (HiMaize™ Starch Australia) 
by 4-week old Sprague-Dawley rats resulted in significant increases of both 
bifidobacteria (p < 0.05) and lactobacilli (p < 0.05) after six weeks of consumption 
(167).  When the diet was prepared using Sunola oil, lactobacilli counts were 8.7 log10 
(colony forming units/g cecal contents) and bifidobacteria counts were 9.2 log10 (colony 
forming units/g cecal contents).  When the high amylose maize starch diet was prepared 
with fish oil, lactobacilli counts did not change, though bifidobacteria counts decreased 
to 8.9 log10 (colony forming units/g cecal contents) (170).   
 The advantages of stimulating beneficial microbes via resistant starch are 
numerous.  Studies have illustrated that resistant starch consumption has the ability to 
lower colonic pH (36) while raising SCFA levels (178), both of which are beneficial to 
host health.   Decreased colonic pH is believed to limit the growth of pH sensitive 
pathogenic bacteria, while simultaneously increasing colonic blood flow and colorectal 
mucosal cell growth (36).  SCFAs, specifically butyrate, are a predominate energy 
source for colonic epithelial cells.  Butyrate‟s ability to arrest cell division via regulation 
of gene expression suggests that it may aid in protection against colorectal cancer (185).    
 Interestingly, preliminary research suggests that soluble corn fiber has shown 
favorable fermentation profiles and prebiotic potential (186), however our results do not 
support these findings.  Using an in vitro model of the human intestine, this study found 
that digestion of soluble corn fiber resulted in increased butyrate levels and decreased 
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ammonia production when compared to a cellulose diet.  They also noted that both 
resistant starch and soluble corn fiber caused a two-fold increase in bifidobacteria 
species.  Based upon the High Performance Anion Exchange Chromatography with 
Pulsed Amperometric Detection (HPAEC-PAD) analysis performed by our laboratory, it 
appears that the physical structure of the soluble corn fiber used in this study is similar to 
a six-carbon monomer (analysis performed by Dr. Karina Pokusaeva, in the laboratory 
of Dr. Joseph Sturino, Texas A&M University) [data not shown]).  This finding supports 
the theory that when ingested, soluble corn fiber may be degraded and utilized by the 
human host, failing to reach the large intestine for bacterial fermentation.  The fact that 
the aforementioned study was utilizing an in vitro model for analysis may explain the 
discrepancies between our findings, as the soluble corn fiber is not undergoing digestion 
and absorption in the human host, therefore it would be highly utilizable for bacterial 
cultures in an in vitro model. 
 Consumption of a diet containing 4% (w/w) soluble corn fiber caused a severe 
washout of both lactobacilli and bifidobacteria populations during initial consumption, 
which may be related to the fiber‟s physical structure and possible bioavailability to the 
human host.  If soluble corn fiber is highly utilized by the host prior to its arrival in the 
large intestine, anaerobic bacteria may not have the opportunity to utilize it for 
fermentation, causing a decrease in proliferation due to lack of substrate.   
Whereas the resistant starch diet contained 2% (w/w) cellulose and 4% resistant 
starch, the 1:1 mixed diet contained 2% (w/w) cellulose, 2% (w/w) resistant starch, and 
2% (w/w) soluble corn fiber.  While the mixed diet contained half the amount of 
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resistant starch found in the resistant starch diet, our results indicate that the effect of 
resistant starch was not dose dependent.  One possible explanation for this finding may 
be the presence of soluble corn fiber in the 1:1 mixed diet.  High bioavailability of 
soluble corn fiber may also have resulted in alterations of host physiology and caloric 
balance.  Gastric emptying is delayed by the activity of receptors in the small intestine, 
which are sensitive to the macronutrient content and energy density of the diet (187).  
When a meal containing highly bioavailable carbohydrates is consumed, this will 
decrease the rate of peristalsis, thus slowing dietary transit time and allowing ample 
opportunity for absorption.  Consumption of the soluble corn fiber diet, which contains 
2% (w/w) cellulose and 4% (w/w) soluble corn fiber as its carbon sources, may lead to a 
decrease in gastric emptying.   
In our study, 2% (w/w) cellulose was incorporated into both the resistant starch 
and soluble corn fiber diets.  While composed of glucose, cellulose has a unique bonding 
pattern, utilizing -1,4 linkages to form a linear glucose polymer.  Cellulose utilizes 
hydrogen bonding to maintain a highly organized structure highly resistant to enzymatic 
digestion (188).  Few microorganisms in the human gastrointestinal tract contain the 
enzymes necessary for cellulose degradation (189). Bacterial species with the ability to 
utilize dietary cellulose include Fibrobacter and Ruminococcus, though some fungi and 
protozoa are also able to derive energy from cellulose catabolism (190). With such 
limited utilization by both host and inhabitants, the incorporation of cellulose into the 
diet does little for the growth of bacterial populations. While the nutrients in cellulose 
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are primarily unutilized by the host, cellulose does cause increased fecal bulking, 
reducing the incidence of constipation (146). 
The soluble corn fiber provided in the diet is likely being absorbed in the small 
intestine, stimulating receptor activity.  While beneficial to the host, the effect of a 
highly bioavailable high carbohydrate meal may not benefit the gastrointestinal 
microbiota.  With gastric emptying delayed by increased small intestine receptor 
stimulation, more carbohydrate is being absorbed in the small intestine, which ultimately 
decreases the amount of carbohydrate that will be available once the gastrointestinal 
contents reaches the large intestine. 
 Macronutrient absorption also plays a key role in regulating gastrointestinal 
blood flow.  After a meal, absorption of macronutrients causes approximately a 200% 
increase in blood flow to the gastrointestinal tract, which lasts for two to three hours 
(191).  Carbohydrate monomers are most effective at increasing gastrointestinal blood 
flow, which has been shown to accentuate gut and mucosa-associated lymphoid tissue, 
which is highly involved in immune function (191).  Consumption of the soluble corn 
fiber diet, which is believed to be highly similar to a glucose monomer, may cause 
higher postprandial hyperemia than consumption of an unavailable carbohydrate such as 
resistant starch. This will cause an increased immune response in the gut, which could 
cause a decrease in bacterial populations deemed by the host as potentially hazardous.  
While consuming a diet that predominantly contains soluble corn fiber is decreasing 
substrate bioavailability to the gastrointestinal microbiota, increasing the macronutrient 
absorption in the human host also plays a large role in the regulation of gastrointestinal 
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function.  The effects of soluble corn fiber on the host physiology may have altered the 
gastrointestinal microbiota, which may explain the cause of non linear relationship 
between the R diet and M diet. 
 During analysis of the data, it was quite apparent that total numbers of native 
lactobacilli and bifidobacteria were markedly different within the Sprague-Dawley rat 
model.  While average bifidobacteria levels fell within the range of 107 to 108 16S rRNA 
gene copies/g feces, lactobacilli levels were much higher, ranging from 109 to 1011 16S 
rRNA gene copies/g feces.  Lactobacilli appear to be high (>107 colony forming units/g) 
in most rat studies, while bifidobacteria levels appear to vary (17).  A real time qPCR 
study using 16S rRNA-specific primers found that Sprague-Dawley rats harbored 
approximately 107 cells/g feces bifidobacteria and approximately 108 cells/g feces of 
lactobacilli (192).  Whereas another study found that the cecal contents of Sprague-
Dawley rats harbored approximately 107 colony forming units/g of bifidobacteria, a 
similar study utilizing Wistar rats harbored extremely low bifidobacteria levels (<103 
colony forming units/g) (170).  One possible cause for the differences in lactobacilli and 
bifidobacteria detection between these studies lies in the quantification techniques used.  
Studies have shown that in comparison to plate counts, real time qPCR targeting the 16S 
rRNA region exhibits increased sensitivity, often resulting in a higher rate of detection 
(193).  Real time qPCR targeting the transaldolase gene, on the other hand, have been 
shown to be more comparable to culture studies (182).  Variable numbers of 16S 
operons between bacterial species and strains may also play a role in increasing qPCR 
estimations.  While sensitive, qPCR may also amplify dead cells that would not be 
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detected by viable plate counts, which may also result in a slightly exaggerated bacterial 
count.    
Lactobacilli levels observed in this study were considerably higher than those 
perceived by other studies.  This may be due in part to the primers used, which were 
designed to amplify 340 base pairs of the lactobacilli 16S rRNA gene, yet also have the 
ability to anneal to the rDNA of Pediococcus, Leuconostoc, and Weissella species (88).  
Therefore, bacterial counts using this primer set may also include enumeration of these 
species, resulting in an increased estimation of lactobacilli populations. 
Bifidobacteria and lactobacilli levels in the adult human vary substantially from 
the levels of this rat model, with the average human harboring approximately 109 to 1010 
colony forming units/g feces of bifidobacteria, and only 106 colony forming units/g feces 
of lactobacilli (30, 84, 85, 183, 194).  Previous studies have shown that while microbial 
enzyme profiles of rats and humans are quite similar, the fecal concentrations of 
indigenous bifidobacteria and lactobacilli are very different (173, 195, 196).  Multiple 
factors contribute to the disparity between the rat and human microbiota, with the main 
factor being location of microbial fermentation.  While fermentation primarily occurs in 
the proximal colon of humans, the cecum is the primary location of fermentation in rats.  
Rats also lack gastric juice in the proximal stomach, allowing for increased colonization 
of obligate anaerobes, which may account for the increased levels of lactobacilli present 
in our samples (195).   
 There are a number of variables that could potentially confound the results of this 
study.  One such variable that may have affected the calculation of 16S rRNA gene copy 
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number is the existence of multiple rrn operons within a target genome.  As was 
previously mentioned, variability in the number of 16S regions means that the copy 
numbers calculated from real-time PCR can only be used as an estimation of true 
bacterial populations.  A recent study has found that the number of bifidobacteria rrn 
operons range from one to five, depending upon species (197).  Therefore, slight 
variations in bifidobacteria copy numbers may occur based upon the species-specific 
colonization of each rat. 
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CHAPTER IV 
IN VITRO UTILIZATION OF SOLUBLE CORN FIBER AND RESISTANT 
STARCH BY BIFIDOBACTERIA AND LACTOBACILLI SPECIES 
 
 
 
Introduction 
 
While the in vivo rat model can provide valuable information regarding the 
utilization of dietary substrates, it can be difficult to analyze specific strain variations in 
fermentative ability.  It has been shown that bacterial populations between individual 
subjects are highly variable, with strain variation shown in both adults and neonates 
(198).  While in vivo experimentation may provide a clear insight into genus and family 
proliferation, it can be difficult to determine which representative species have the 
ability to utilize certain dietary substrates.  A recent in vitro study examining the 
proliferation of three specific bifidobacteria strains after cultivation with three unique 
resistant starches found that the growth of each strain is indeed dependent on substrate 
type (199).  Even though all substrates were classified as type three retrograded starches, 
strain performance varied depending upon which compound was provided.  A large 
variation in single substrate utilization was also observed between the three strains, 
promoting the idea that strain growth is variable.  Table 12 provides further insight into 
this study. 
Species-specific in vitro experiments may provide clues to what is occurring in 
subjects harboring each specific strain, while also allowing further exploration into the 
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ability of bacterial populations to utilize these dietary sources in the absence of 
complications in the host environment.  As previous in vivo studies have shown the 
varying ability of bifidobacteria and lactobacilli to utilize resistant starch and soluble 
corn fiber, utilization of in vitro methods may allow some insight into the effects of 
ingestion on the availability of these indigestible but fermentable polysaccharides.   
 
Materials and Methods 
 
Bacterial Strains and Cultivation Conditions 
Nine strains of Bifidobacterium (including representatives from eight different 
species) and 11 strains of Lactobacillus (including representatives from nine different 
species) were assayed for their ability to ferment 1% PROMITOR soluble corn fiber 
70 (Tate & Lyle) and 1% PROMITOR resistant starch (Tate & Lyle) as a sole source 
of fermentable carbon. The strains used in this study are listed in Table 13.  For these 
experiments, 10% (w/v) solutions of soluble corn fiber and lactose were sterilized by 
filtration (0.45m pore size), while a 10% (w/v) suspension of resistant starch was 
sterilized by autoclaving (20 minutes at 121C) due to its poor aqueous solubility.  
Modified Garche broth (composition, g/L of distilled water: beef extract (Difco) 20; 
yeast extract (EMD Chemicals), 2; L-cysteine hydrochloride (Sigma-Aldrich), 0.4; 
lactose (EMD Chemicals), 10; sodium acetate trihydrate (Amresco), 9.9512; 
MgSO4·7H2O (Sigma-Aldrich), 0.12; Na2HPO4 (Amresco), 0.9915; KH2PO4 (Amresco), 
2) (200) was supplemented with sterile lactose, soluble corn fiber, or resistant starch to a 
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final concentration of 1% (w/v); the resultant media are referred to as Garche-L, Garche-
SCF, and Garche-RS.  For enumeration, bifidobacteria were plated onto Reinforced 
Clostridial Medium (Oxoid) agar (RCA). For solid media, agar (BD) was supplemented 
(15g/L) to the medium base prior to autoclaving.  Samples were incubated 37C (static) 
in a vinyl anaerobic chamber (Coy Laboratory Products) under anaerobic conditions (5% 
CO2, 5% hydrogen, 90% nitrogen).  
 
Strain-Dependent Utilization of Resistant Starch and Soluble Corn Fiber 
To further examine the ability of various Bifidobacterium species to utilize 
resistant starch as a sole fermentable carbon source, five strains of Bifidobacterium were 
inoculated into Garche broth or Garche broth supplemented with either 1% (w/v) 
resistant starch or 1% lactose (w/v).  These media (10 mL) were individually inoculated 
at 1% (v/v) with overnight cultures of B. longum DJ010A, B. adolescentis ATCC 15703, 
B. infantis NRRL B-41661, B. bifidum NRRL B-41410, or B. animalis subspecies 
animalis NRRL B-41406.   
Tubes were incubated anaerobically at 37°C for ten hours.  Immediately prior to 
incubation and vortexing, serial decimal dilutions of each tube were prepared. Once 
vortexed, 100μL of each serial dilution was plated in triplicate on Reinforced Clostridial 
Agar (RCA) plates.  Plates were incubated anaerobically for 72 hours at 37°C. 
 After allowing the inoculated tubes to incubate for 10 hours, the process of 
serially diluting each tube and plating was repeated in triplicate.  Plate counts were 
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performed for each timepoint and carbon source, to determine colony-forming units 
(CFU) per 1mL of culture.   
 
Results  
 
Strain-Dependent Utilization of Resistant Starch and Soluble Corn Fiber 
 Three technical replicates for each dilution were created, and two biological 
replicates were performed.  Analysis was executed using paired sample t-tests. 
Upon completion of the previous experiments, it became clear that the ability for 
utilization of resistant starch or soluble corn fiber is variable between strains.  Two 
strains, one previously exhibiting weak growth and one exhibiting strong growth, were 
chosen for further experimentation. A plate count study was conducted to determine the 
growth capabilities of B. longum NRRL B-41409 and B. bifidum NRRL B-41410 on 
modified RCA plates after 24 hour inoculation in media containing either 1% soluble 
corn fiber or 1% resistant starch.   
B. longum NRRL B-41409 and B. bifidum NRRL B-41410 were cultivated 
independently in Garche-SCF and Garche-RS.  Ten mL aliquots of each medium were 
inoculated and allowed to incubate for 24 hours anaerobically at 37ºC.  Serial decimal 
dilutions (10-1 through 10-10) were made for each culture using sterile nano-pure water.  
Dilutions 10-3 through 10-10 were plated on separate RCA plates using a sterile glass 
hockey stick and incubated for 72 hours anaerobically at 37ºC. 
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Utilization of Resistant Starch and Soluble Corn Fiber  
All bifidobacteria and lactobacilli strains tested were successfully able to utilize 
Garche agar plates containing 1% soluble corn fiber or 1% resistant starch, although 
degree of growth varied between strains (Table 14).  It appears that most bifidobacteria 
strains had difficulty utilizing the resistant starch in vitro.  Weak growth (+) was 
displayed in all bifidobacteria strains except for B. bifidum NRRL B-41410, which 
exhibited moderate (++) colonization after 72 hours (Table 14). 
In general, growth of bifidobacteria strains utilizing the soluble corn fiber was 
equal to or greater than growth exhibited by these strains when provided resistant starch.  
B. adolescentis ATCC 15703 and B. infantis NRRL B-41661 exhibited strong growth 
(+++) when cultivated on Garche agar plates prepared with a soluble corn fiber carbon 
source.  Apart from B. longum NRRL B-41409, which exhibited weak growth (+) on 
both carbon sources, the remaining bifidobacteria strains demonstrated moderate growth 
(++) when provided soluble corn fiber (Table 14).   
 Lactobacilli utilization of both carbon sources was markedly similar.  Of the 11 
lactobacilli strains examined, only L. gasseri ATCC 19992 and L. rhamnosus ATCC 
7469 exhibited stronger growth when offered soluble corn fiber as opposed to resistant 
starch.  Only L. rhamnosus NRRL B-442 and L. rhamnosus ATCC 7469 exhibited 
strong growth (+++) when cultivated in soluble corn fiber.  While all 11 strains of 
Lactobacillus successfully utilized resistant starch, only L. rhamnosus NRRL B-442 
exhibited strong growth (+++) when cultivated in either carbon source (Table 14). 
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Bifidobacteria Strains Exhibit Increased Growth after Ten-Hour Cultivation in Resistant 
Starch and Soluble Corn Fiber 
 After five bifidobacteria strains cultured in Garche-RS or Garche-L were 
analyzed via plate counts, it was found that three of the five strains cultivated with 
resistant starch displayed an increase in growth after ten hours (Table 15).  B. longum 
DJ010A (p = 0.030; n = 6), B. bifidum NRRL B-41410 (p = 0.000; n = 6), and B. 
animalis subspecies animalis NRRL B-41406 (p = 0.008; n = 6) all showed a significant 
increase in CFU per mL culture when cultivated with resistant starch (α = 0.05; analysis 
performed using Paired Sample T-test; SPSS 15.0 for Windows).  B. bifidum NRRL B-
41410 displayed the largest increase in growth when provided the resistant starch carbon 
source, with a p-value of 0.00 (n = 6) (Figure 22).   
 When consuming lactose, all five strains displayed a significant increase in 
growth after the ten-hour incubation period (p values  0.021) (Table 15).  For all 
strains, fold change was larger when cultivated with lactose (Figure 23). 
 
B. bifidum NRRL B-41410 Exhibits Increased Utilization of Resistant Starch and Soluble 
Corn Fiber  
B. longum NRRL B-41409 and B. bifidum NRRL B-41410 were cultivated in 
Garche-SCF and Garche-RS for 24 hours, then enumerated on RCA agar plates for 72 
hours. When initially cultivated in a 1% soluble corn fiber Garche medium, B. longum 
NRRL B-41409 formed 1.02×107 CFU/mL, while B. bifidum NRRL B-41410 formed 
2.25×108 CFU/mL.  When utilizing a 1% resistant starch carbon source, B. longum 
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NRRL B-41409 formed 4.0×106 CFU/mL, while B. bifidum NRRL B-41410 formed 
4.00×107 CFU/mL.  Both strains displayed higher growth when utilizing the soluble corn 
fiber carbon source.  For both carbon sources, B. bifidum growth was one log order 
larger than B. longum growth (Table 16).   
 
Discussion 
 
 The PROMITOR resistant starch (Tate & Lyle) utilized in this study is 
categorized as RS3, as indicated by product literature. While in vivo results indicate that 
only resistant starch causes a significant increase in bifidobacteria populations, in vitro 
results suggest that utilization of soluble corn fiber causes higher levels of bacterial 
growth.  Visual inspection of lactobacilli and bifidobacteria strains grown on Garche 
agar plates containing one of the two carbon sources displayed marked increases in 
bacterial growth when soluble corn fiber was provided (Table 14).  This finding was 
echoed in plate count studies, which clearly showed higher levels of bacterial growth 
when grown in media containing soluble corn fiber as its sole carbon source (Table 16).   
 As previously mentioned, multiple factors affect the ability of gastrointestinal 
microbiota to utilize dietary sources.  Carbon sources that are easily accessible to 
microbes will be highly fermented, allowing for increased bacterial proliferation.  If a 
dietary component is unsuccessful in reaching the large intestine or is physically 
inaccessible, bacterial growth will be decreased (139).  Whereas the S diet did not cause 
an increase in lactobacilli and bifidobacteria populations in vivo, the R diet was able to 
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stimulate the proliferation of bifidobacteria, suggesting that the availability of soluble 
corn fiber and resistant starch may be dissimilar in the large intestine.  While soluble 
corn fiber causes a large increase in bacterial proliferation in vitro, it fails to produce a 
similar increase in the rat colon.   
One potential reason for this disparity may lie in soluble corn fiber‟s digestibility 
by the human host.  High Performance Anion Exchange Chromatography with Pulsed 
Amperometric Detection (HPAEC-PAD) analysis of the soluble corn fiber used in these 
studies suggests that the structure of this molecule is similar to a six-carbon monomer.   
This finding supports the theory that when ingested, soluble corn fiber may be degraded 
and utilized by the human host, failing to reach the large intestine for bacterial 
fermentation.  HPAEC-PAD analysis of resistant starch revealed chemically-distinct 
polysaccharides with different degrees of polymerization, which is much more likely to 
reach the large intestine intact (analysis performed by Dr. Karina Pokusaeva, 
Postdoctoral Research in the laboratory of Dr. Joseph Sturino, Texas A&M University) 
[data not shown]. 
 While soluble corn fiber may be affected by human digestion, it is also possible 
that resistant starch is altered during transit through the gastrointestinal tract.  While 
resistant starch‟s high degree of polymerization (DP = 25) increases the probability that 
it will reach the large intestine, exposure to the severe acidic pH of the stomach and 
digestive enzymes may result in partial digestion of the molecule.  Therefore, passage of 
resistant starch through the gastrointestinal tract may decrease molecule size and 
improve its availability to bacterial populations, increasing its fermentation (201). 
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 When grown on Garche plates containing resistant starch or soluble corn fiber, it 
appears that lactobacilli, regardless of species, are more capable of utilizing resistant 
starch than bifidobacteria.  One possible reason for this observation may lie in the 
oxygen tolerance of these bacterial groups.  Lactobacilli are commonly located in 
multiple regions of the gastrointestinal tract.  While prominent in the stomach and small 
intestine, lactobacilli have also been isolated in the oral cavity, where oxygen levels are 
considerably higher than the large intestine (28).  In comparison, bifidobacteria are strict 
anaerobes, residing in the large intestine where oxygen is minimal (68).  While 
incubated anaerobically, plates were briefly exposed to oxygen during inoculation.  This 
exposure may have stunted the growth of bifidobacteria species, while affecting 
lactobacilli to a lesser degree. 
 When bifidobacteria species were cultivated in resistant starch and lactose over a 
ten-hour time period, growth during lactose consumption was markedly higher than 
during resistant starch consumption.  Lactose is often used as a control during in vitro 
cultivation experiments, as studies have shown that bifidobacteria can catabolize 
approximately 90% of lactose provided to a continuous culture (202).  Supplementation 
of bifidobacteria have been successful shown to decrease symptoms of lactose 
intolerance by salvaging unabsorbed lactose (202).   Lactose, a disaccharide composed 
of glucose and galactose bound by a β-1,4-glycosidic bond, is readily digested by most 
bifidobacteria, which produces the enzyme β-galactosidase to effectively cleave this 
molecule (202).  Therefore, it would be expected that bifidobacteria would utilize lactose 
to a higher extent, as they are fully equipped to digest this disaccharide.  Resistant 
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starch, being a D-glucose polymer, is not as easily utilized as lactose, which was 
reflected in the growth capabilities of the five bifidobacteria strains tested. 
 It is clear from these experiments that the ability to utilize various carbon sources 
is species dependent.  While general trends may be identified within bacterial groups, 
proliferation was clearly different between species and strains. Experiments analyzing 
the growth of two strains: B. longum NRRL B-41409 and B. bifidum NRRL B-41410 
provided data supporting this theory.  In all experiments performed, B. bifidum displayed 
superior growth.  B. bifidum was better able to utilize both resistant starch and soluble 
corn fiber. It has been shown that strain composition is variable between human 
individuals, even though the relative population of bacterial groups may be similar (10).  
Therefore, the effectiveness of a prebiotic may also vary from person to person, as the 
species composition of commensal microbiota could determine its degree of utilization 
in the large intestine. 
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CHAPTER V 
SUMMARY  
 
 It is estimated that 90% of cells in the human body belong to its microbial 
inhabitants, suggesting that bacteria foster the ability to profoundly affect host health and 
gastrointestinal function (1).  The relationship between host and bacteria is believed to 
be symbiotic, as both parties positively benefit from one another (7, 8).  As bacteria 
salvage nutrients from the human diet to facilitate their proliferation and colonization in 
the gastrointestinal tract, the human host reaps numerous benefits, including the 
utilization of short chain fatty acids, vitamin production, and increased absorption of 
minerals (106).  The presence of beneficial bacteria also improves the host immune 
defense against pathogens, stimulating mucin secretion and producing antibacterial 
peptides (2, 110, 114). 
 As the benefits of a healthy gastrointestinal tract mount, research has focused on 
means to increase the colonization of beneficial species.  While the consumption of live 
cultures has been proven beneficial in promoting such species, permanent colonization 
of probiotic bacteria has yet to be achieved and the shelf-life of these products is short 
(133).  Prebiotics, which are functional foods that potentially modulate the composition 
and activity of gastrointestinal microbiota, are now being explored as an alternative 
means to increase beneficial species (137).    
 A Sprague-Dawley rat model was utilized to determine the prebiotic properties of 
four fermentable diets over a 43-day period.  DNA was extracted from fecal material, 
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and quantitative PCR using 16S rRNA taxon-specific primers was used to determine the 
number of Bifidobacterium-species and Lactobacillus-group 16S rRNA gene copies per 
gram of feces. 
 At the completion of the study, consumption of R diet caused a 26.54-fold 
increase in bifidobacteria 16S rRNA gene copies/g feces.  Initial bifidobacteria levels 
when consuming chow diet (prior to introduction of the resistant starch diet) were 
2.17107 16S rRNA gene copies/g feces, yet after 43 days consuming the experimental 
diet, 5.75108 16S rRNA gene copies/g feces were observed.  The colonization of 
bifidobacteria peaked during day 36 of the study, as the resistant starch diet caused a 
101-fold increase in bifidobacteria levels in comparison to the C diet.  Consumption of 
the M diet did cause a 9.61-fold increase in bifidobacteria colonization (p = 0.009), 
though the effect of this diet was not dose-dependent in comparison to the R diet.  Levels 
of bifidobacteria experienced a 1.68-fold increase during consumption of the C diet, 
increasing from 4.21106 16S rRNA gene copies/g feces to 7.06106 16S rRNA gene 
copies/g feces by the completion of the study.  No significance increase or decrease was 
observed during consumption of the S diet.   
 Consumption of the S diet (p = 0.018), M diet (p = 0.004), and C diet (p = 
0.037) caused a significant decrease in lactobacilli populations.  Consumption of the 
resistant starch diet resulted in no significant difference between lactobacilli populations 
on day 1 and day 43 (p = 0.628).  This experiment displayed the ability of resistant 
starch to markedly increase bifidobacteria populations in comparison to the other three 
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diets.  Our results suggest that RS3 may be utilized as a prebiotic to stimulate the 
proliferation of bifidobacteria in vivo.   
As previously discussed, resistant starch is believed to be effective in stimulating 
the proliferation of colonic bacteria, as has been shown in numerous in vivo studies 
utilizing plate count methods for bacterial analysis. The advantages of stimulating 
beneficial microbes via resistant starch are numerous, as studies have illustrated that 
resistant starch consumption has the ability to lower colonic pH (36) while raising SCFA 
levels (178), which are both beneficial to host health. 
 Interestingly, preliminary research suggested that soluble corn fiber has shown 
favorable fermentation profiles and prebiotic potential (186), however our results did not 
support these findings.  We hypothesized that soluble corn fiber may be degraded and 
utilized by the human host, failing to reach the large intestine for bacterial fermentation.  
This may effect host physiology by decreasing gastric emptying, increased blood flow to 
the gut, and accentuating innate immune function (191).  We also observed a large 
disparity between the relative levels of lactobacilli and bifidobacteria enumerated from 
fecal samples. One possible reason for this disproportion may be the use of quantitative 
PCR and 16S rRNA group-specific primers, which can result in an overestimation of 
viable bacteria. The specific primers used for lactobacilli quantification, Lac1 and Lac2, 
also possess the ability to anneal to the rDNA of Pediococcus, Leuconostoc, and 
Weissella species, which could also result in overestimation of lactobacilli (88). 
In vitro cultivation techniques were also employed to examine the strain-
dependent variations in prebiotic utilization.  Cultivation of various bifidobacteria and 
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lactobacilli strains on Garche agar plates containing 1% resistant starch or 1% soluble 
corn fiber confirmed that all strains were able to utilize both carbon sources, though 
degrees of proliferation were strain-dependent.  It appeared that most bifidobacteria 
strains had difficulty utilizing the resistant starch in vitro.  Weak growth (+) was 
displayed in all bifidobacteria strains except for B. bifidum NRRL B-41410, which 
exhibited moderate (++) colonization after 72 hours.  Lactobacilli utilization of both 
carbon sources was markedly similar.  Of the 11 lactobacilli strains examined, only L. 
gasseri ATCC 19992 and L. rhamnosus ATCC 7469 exhibited stronger growth when 
offered soluble corn fiber as opposed to resistant starch.  Only L. rhamnosus NRRL B-
442 and L. rhamnosus ATCC 7469 exhibited strong growth (+++) when cultivated in 
soluble corn fiber.  This study displayed the increased utilization of soluble corn fiber in 
vitro, which suggests that this functional food may have a higher bioavailability in 
comparison to resistant starch. 
 The proliferation of two bifidobacteria strains, previously identified as exhibiting 
weak and strong growth, were utilized to further examine the strain-dependent utilization 
of resistant starch and soluble corn fiber.  Plate count studies confirmed the increased 
ability of B. bifidum NRRL B-41410 to utilize resistant starch and soluble corn fiber in 
comparison to B. longum NRRL B-41409.  Plate counts of both strains conducted after 
24-hour cultivation in Garche media containing 1% resistant starch or 1% soluble corn 
fiber also exhibited stronger growth by B. bifidum NRRL B-41410.  When provided a 
resistant starch carbon source, B. bifidum NRRL B-41410 (4.0107 CFU/ml) exhibited a 
10-fold increase in bacterial numbers over B. longum NRRL B-41409 (4.0106 
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CFU/ml).  When cultivated with soluble corn fiber, B. bifidum NRRL B-41410 
(2.25108 CFU/ml) exhibited a 22-fold increase over B. longum NRRL B-41409 
(1.02107 CFU/ml).  These studies support the notion that utilization of carbon sources 
is strain-dependent.  Due to the strain variability between human subjects, the 
effectiveness of prebiotic substances may vary between consumers, as certain 
populations may better utilize these functional foods. 
 Five bifidobacteria strains were also examined to determine their ability to utilize 
resistant starch over a 10-hour period in comparison to a lactose control.  All 
bifidobacteria strains exhibited stronger growth when presented the lactose carbon 
source.  When provided resistant starch, B. longum DJ010A (p = 0.030), B. bifidum 
NRRL B-41410 (p = 0.000), and B. animalis subspecies animalis (p = 0.008) all 
displayed significant increases in growth after ten hour incubation.  B. infantis NRRL B-
41661 exhibited a nonsignificant increase after 10 hours (p = 0.200) B. adolescentis 
ATCC 15703 did not experience an increase in growth after inoculation (fold change = 
0.9188). 
 When cultivated with lactose, B. longum DJ010A (p = 0.008), B. adolescentis 
ATCC 15703 (p = 0.000), B. infantis NRRL B-41661 (p = 0.000), B bifidum NRRL B-
41410 (p = 0.021), and B. animalis subspecies animalis NRRL B-41406 (p = 0.000) all 
exhibited significant increases in growth after 10 hours.  Results of this study indicated 
that bifidobacteria strains experienced decreased utilization of resistant starch in 
comparison to the lactose control, as well as confirmed our hypothesis that the utilization 
of resistant starch is strain-dependent. 
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 While in vivo results indicate that only resistant starch caused a significant 
increase in bifidobacteria populations, in vitro results suggest that utilization of soluble 
corn fiber caused higher levels of bacterial growth.  Whereas the S diet did not cause an 
increase in lactobacilli and bifidobacteria populations in vivo, the R diet was able to 
stimulate the proliferation of bifidobacteria, suggesting that the availability of soluble 
corn fiber and resistant starch may be dissimilar in the large intestine.  While soluble 
corn fiber causes a large increase in bacterial proliferation in vitro, it fails to produce a 
similar increase in the rat colon.   
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APPENDIX 
 
 
 
 
TABLE 1     Factors affecting the bacterial colonization of the gastrointestinal tract 1 
Host Microbiological Dietary Environmental 
Host Age & 
Genetics 
Competition for 
Mucosal and Food 
Particle Adhesion 
Sites 
Availability/Accessibility 
of Various Carbon 
Sources 
Total Titratable 
Acidity 
Disease State, 
Drug and 
Antibiotic Use  
Bacterial Genetic, 
Biochemical, and 
Physiological 
Traits 
Fermentability of 
Substrate  
Reduction-
Oxidation 
Potential 
IgA and 
lysozyme 
production 
Metabolite 
Production by 
Commensal 
Bacteria for 
Inhibition of 
Invading Species 
Percentage of 
Polysaccharides in the 
Diet 
Geographical and 
Cultural Factors 
Associated With 
the Host 
Production of 
Pancreatic and 
Digestive 
Secretions 
Bacterial Secretion 
of Antagonistic 
Substances  
Bond Formation of 
Polymers 
Regulation of Fat 
Storage 
1Modified from Macfarlane S, Macfarlane GT, 2004.  (11) 
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TABLE 2     Survey of in vivo experiments analyzing prebiotic responses to soluble corn fiber and resistant starch 
Type Compound Form Source Supplementation Subjects n Length of Study Assessment Method Result References 
In vivo 
Pea cultivar 
Maria (Pisum 
sativum, L.) 
RS3  
 
Grain 
collection of 
the National 
Horticulture 
Research 
Center 
 
12.8 ± 0.4 g/100g 
diet 
21-23 day old 
male Wistar 
rats 
4 28 days 
plate count method 
(CFU/g cecal 
contents) 
Significant increase in  
bifidobacteria in 
comparison to control 
(164) 
In vivo 
Chickpea 
(Cicer 
arietinum, L.) 
RS3 
 
Grain 
collection of 
the National 
Horticulture 
Research 
Center 
 
14.5 ± 0.3 g/100g 
diet 
21-23 day old 
male Wistar 
rats 
4 28 days 
plate count method 
(CFU/g cecal 
contents) 
Significant increase in  
bifidobacteria in 
comparison to control 
(164) 
In vivo 
Oat Bran / 
Novelose 330 
Cereal / RS3 
blend 
 
Prepared in  
twin-screw 
extruder 
ERMAFA 
DS 6·0 / 
National 
Starch and 
Chemical 
(Hamburg, 
Germany) 
 
114 g/kg diet Young male Wistar rats 10 42 days 
plate count method 
(CFU/g feces) 
Significant increase in  
bifidobacteria in 
comparison to control 
(166) 
In vivo 
High 
Amylose 
(amylomaize) 
Starch 
RS2  
Himaize  
Starch 
Australia 
Amount of RS2 
not given; 12.6 
CFU/day of 
freeze-dried B. 
longum CSCC 
1941 (prebiotic 
supplement) 
Young Adult 
Male pigs 
(White strain) 
11 7 days plate count method (CFU/g feces) 
 
Increased fecal bulk 
 
8.91 log CFU/g fecal 
weight bifidobacteria 
(significantly higher than 
control) 
 
No significant increase in 
bifidobacteria when only 
resistant starch provided 
 
(169) 
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TABLE 2     (Continued) 
Type Compound Form Source Supplementation Subjects n Length of Study Assessment Method Result References 
In vivo 
High 
Amylose 
(amylomaize) 
Starch 
RS2 
Himaize 
Starch 
Australia 
223 grams/kg 
(10% of diet) 
4 Wk Old Male 
Sprague 
Dawley Rats 
16 6 weeks 
Plate Count Method 
(log CFU/g cecal 
contents) 
 
Lactobacillus: 8.7 log 
CFU/g (significantly 
higher than control, 
regardless of dietary fat 
source) 
 
Bifidobacteria: 9.2 log 
CFU/g when Sunola oil in 
diet; 8.9 log CFU/g when 
fish oil in diet (both 
significantly higher than 
control) 
 
(167) 
In vivo Novelose 260 RS3 
National 
Starch and 
Chemical 
Company 
202 grams/kg 
(10% of diet) 
4 Wk Old Male 
Sprague 
Dawley Rats 
16 6 weeks 
Plate Count Method 
(log CFU/g cecal 
contents) 
 
Lactobacillus: 8.9 log 
CFU/g  (significantly 
higher than control, 
regardless of dietary fat 
source) 
 
Bifidobacteria: 9.4 log 
CFU/g when Sunola oil in 
diet; 8.7 log CFU/g when 
fish oil in diet (both 
significantly higher than 
control) 
 
(167) 
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TABLE 2     (Continued) 
Type Compound Form Source Supplementation Subjects n Length of Study Assessment Method Result References 
In vivo 
High 
Amylose 
Maize Starch 
(85% 
amylose) 
RS2 
Starch 
Australia 
Lane Cove, 
Australia 
515 grams/kg Large White Crossbred Pigs 6 21 days 
Plate Count Method 
(CFU/gram wet 
feces) 
 
Lactobacillus (in digesta): 
7.51 log CFU/g 
(significantly higher than 
control) 
 
Lactobacillus (in feces): 
7.96 log CFU/g 
 
Bifidobacteria (in 
digesta): 8.12 log CFU/g 
(significantly higher than 
control) 
 
Bifidobacteria (in feces): 
8.45 log CFU/g 
(significantly higher than 
control) 
 
(168) 
In vivo 
High 
Amylose 
Maize Starch 
(85% 
amylose) 
note: 
Subjected to 
Hydrothermal 
Treatment 
RS2 
Starch 
Australia 
Lane Cove, 
Australia 
515 grams/kg Large White Crossbred Pigs 6 21 days 
Plate Count Method 
(CFU/gram wet 
feces) 
 
Lactobacillus (in digesta): 
7.70 log CFU/g 
(significantly higher than 
control) 
 
Lactobacillus (in feces): 
7.52 log CFU/g 
 
Bifidobacteria (in 
digesta): 8.12 log CFU/g 
(significantly higher than 
control) 
 
Bifidobacteria (in feces): 
7.89 log CFU/g 
(significantly higher than 
control) 
 
(168) 
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TABLE 2     (Continued) 
Type Compound Form Source Supplementation Subjects n Length of Study Assessment Method Result References 
In vivo 
 
Amylomaize 
Starch (Culture 
Pro™ 958N) 
(80% amylose) 
 
Not 
provided 
Penford, 
Australia 
400grams/kg co-
administered with 
200µL B. lafti B8 
12 week old, 
female balb/c 
mice 
6 6 days 
Plate Count Method 
(log CFU/g wet 
feces) 
B. lafti B8: 8.0 ± 0.6 log 
CFU/g 
(significantly higher than 
waxy corn starch control) 
(173) 
In vivo 
Amylomaize 
Starch (Culture 
Pro™ 958N) 
(80% amylose) 
Not 
provided 
Penford, 
Australia 400 grams/kg 
12 week old, 
female balb/c 
mice 
6 4 weeks 
Plate Count Method 
(log CFU/g wet 
feces) 
 
Total Bifidobacteria: 8.2 
± 0.5 log CFU/g 
(significantly higher than 
waxy corn starch control) 
 
Total Lactobacilli: 7.7 ± 
0.4 log CFU/g ( not 
significantly higher than 
waxy corn starch control) 
 
(173) 
In vivo 
HiMaize 958 
(unmodified 
high amylose 
maize starch) 
RS3 
National 
Starch and 
Chemical 
Company 
10grams/100gram 
diet; co-
administered with 
1.0 × 1010 
CFU/gram diet of 
either L. 
acidophilus or B. 
lactis 
7 week old male 
Sprague Dawley 
Rats 
8 4 weeks 
Plate Count Method 
(CFU/gram wet 
fecal weight) 
 
When L. acidophilus 
supplemented: 
Lactobacilli: 9.04 ± 0.9 
CFU/g (significantly 
higher than control) 
Bifidobacteria: 9.38 ± 0.8 
CFU/g (NSD) 
 
When B. lactis 
supplemented: 
Lactobacilli: 9.29 ± 0.5 
CFU/g 
Bifidobacteria: 9.83 ± 0.8 
CFU/g 
 
(203) 
In vivo 
 
Debranched 
Retrograded 
Tapioca 
Maltodextrin 
 
RS3 Actistar, Cerestar 10grams/day 
Adult Humans 
(mean age = 30 
years old) 
8 15 days 
Plate Count Method 
(CFU/gram fresh 
feces) 
No significant increase in 
bifidobacteria when 
compared to placebo 
(204) 
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TABLE 2     (Continued) 
Type Compound Form Source Supplementation Subjects n Length of Study Assessment Method Result References 
In vivo 
Modified 
Retrograded 
Potato Starch 
(10% RS 
content) 
RS3 Not Provided 400 grams/kg 8 week old male wistar rats 10 5 months 
Plate Count Method 
(log CFU/g dry feces) 
 
 
Lactobacilli: 10.3 log CFU/g 
(significantly higher than 
control) 
 
Bifidobacteria: NSD from 
control 
 
(170) 
In vivo 
CrystaLean 
retrograded 
amylose starch 
RS3 SunOpta, Inc. 150grams/kg 
6-8 week old 
Human Flora-
Associated Fisher 
Rats 
(Italian donors)  
8 4 weeks 
Plate Count Method 
(log CFU/gram wet 
cecal content weight) 
 
Lactobacilli: 7.69 ± 0.24 log 
CFU/gram (significantly 
higher than control) 
 
Bifidobacteria: 8.69 ± 0.52 
log CFU/gram (significantly 
higher than control) 
 
(165) 
In vivo 
 
Native Granular 
Potato  
(60% RS 
content) 
 
RS2 
Emsland 
Stärke 
Gmbtl, 
Emlichheim, 
Germany 
100 grams/kg 8 week old male wistar rats 10 5 months 
Plate Count Method 
(log CFU/g dry feces) 
Bifidobacteria and 
Lactobacilli not significantly 
different than control 
(170) 
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TABLE 3     Bacterial strains used in this study 
Strain Origin Source 
Lactobacillus acidophilus ATCC 4356 Human       ATCC 1 
Bifidobacterium adolescentis ATCC 15703 Human Adult Feces       ATCC  
1 ATCC: American Type Culture Collection
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TABLE 4     Dietary sample size and polysaccharide additives 
Diet Sample Size  Polysaccharide Additives (w/w) 
 DSS 1 control  
C 20 10 6% cellulose 
S 20 10 2% cellulose combined with 4% soluble corn fiber 
R 20 10 2% cellulose combined with 4% resistant starch 
M 20 10 2% cellulose combined with 2% resistant starch and 2% soluble corn fiber 
 1 Dextran Sodium Sulfate 
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TABLE 5    Composition of the experimental diets 
Component(s) g/100g 
 C 1 S 2 R 3 M 4 
Experimental Polysaccharide 
    
     Cellulose 6.00 2.00 2.00 2.00 
     Soluble corn fiber - 4.00 - 2.00 
     Resistant starch - - 2.00 2.00 
Subtotal: 6.00 6.00 6.00 6.00 
     
Base Formulation     
     Dextrose 51.06 51.06 51.06 51.06 
     Casein 22.35 22.35 22.35 22.35 
     DL-methionine 0.34 0.34 0.34 0.34 
     Mineral mix 3.91 3.91 3.91 3.91 
     Vitamin mix 1.12 1.12 1.12 1.12 
     Choline bitartrate 0.22 0.22 0.22 0.22 
     Corn oil 15.00 15.00 15.00 15.00 
     
Total 100 100 100 100 
1 C: cellulose 
2 S: soluble corn fiber 
3 M: mixed diet 
4 R: resistant starch 
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FIGURE 1  Representative fecal pellets from Sprague-Dawley rats following the 
consumption of A) cellulose, B) resistant starch, C) soluble corn fiber, and D) mixed diet 
for 6 weeks. 
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TABLE 6    The 16S rRNA gene-specific oligonucleotide primers used in this study 
Target Primer name Sequence (5′3′) 1 Annealing temperature (C) Fragment size Gene target Position
2 References 
Lactobacillus-group Lac1 AGCAGTAGGGAATCTTCCA 60 
327 16S 
352 
(88) 
 Lac2 ATTYCACCGCTACACATG 60 679 
Bifidobacterium spp g-Bifid-F CTCCTGGAAACGGGTGG 55 
550 16S 
153-169 
(77) 
 g-Bifid-R GGTGTTCTTCCCGATATCTACA 55 699-720 
 1 Y, Nucleotide degeneracy (either C or T)  
    2 Nucleotide position based on the Escherichia coli 16s rRNA gene sequence  
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Feces
Homogenization DNA Extraction
Feces in     
TRIS Buffer
DNA
Real Time PCR 
GCGC
ATAT
GC
GCGCATATGC
GCGCATATGC
GCGCATA
TGC
Group-Specific 16S 
rRNA Amplicons
 
FIGURE 2     Flow diagram of processing and quantitative analysis.  DNA was extracted from fecal material using the Soil 
Kit (MP Biomedicals).  Quantitative PCR using 16S rRNA taxon-specific primers was used to determine the number of 
Bifidobacterium-species and Lactobacillus-group 16S rRNA gene copies per gram feces. 
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TABLE 7    Standard curve composition 
Well DNA (ng/µL) 1 
1 2.0×10-1 
2 2.0×10-2 
3 2.0×10-3 
4 2.0×10-4 
5 2.0×10-5 
6 2.0×10-6 
7 - 
            1 Genomic DNAs extracted from Lactobacillus 
acidophilus ATCC 4356 and Bifidobacterium 
adolescentis ATCC 15703 were decimally 
diluted to the noted final in-reaction 
concentrations. Following quantitative PCR, the 
fluorescent signals were used to generate a 
DNA template concentration-dependant dose-
response curve  
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FIGURE 3 Linear regression resulting from an example standard curve. Generated from serial decimal dilutions of 
Lactobacillus acidophilus ATCC 4356.  DNA concentrations indicated for each point of the standard curve. Point indicated 
by DAFE contains only feces extract. Sample identification numbers refer to DNA concentrations displayed in Table 7.     
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FIGURE 4 The recovery of DNA from the feces of individual Sprague-Dawley rats consuming R diet as a function of time.  Fecal 
samples were collected from individual rats at 3-hour increments during the dark cycle over a 12-hour period. One fecal pellet from each 
3-hour timepoint was randomly selected and combined to produce a representative sample of daily fecal movements. Fecal samples were 
weighed, combined with an appropriate volume of 10 mM Tris Buffer (pH = 8.0), and homogenized using a FastPrep (MP Biomedicals) 
for 2 minutes at 4.0 m/s.  500mL of the resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for Soil (MP 
Biomedicals) following manufacturer‟s directions and DNA concentration was assayed by spectrophotometry.  
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FIGURE 5 The recovery of DNA from the feces of individual Sprague-Dawley rats consuming M diet as a function of time.  Fecal samples were 
collected from individual rats at 3-hour increments during the dark cycle over a 12-hour period. One fecal pellet from each 3-hour timepoint was 
randomly selected and combined to produce a representative sample of daily fecal movements. Fecal samples were weighed, combined with an 
appropriate volume of 10 mM Tris Buffer (pH= 8.0), and homogenized using a FastPrep (MP Biomedicals) for 2 minutes at 4.0 m/s.  500mL of the 
resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for Soil (MP Biomedicals) following manufacturer‟s directions and 
DNA concentration was assayed by spectrophotometry. 
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FIGURE 6 The recovery of DNA from the feces of individual Sprague-Dawley rats consuming S diet as a function of time.  Fecal samples 
were collected from individual rats at 3-hour increments during the dark cycle over a 12-hour period. One fecal pellet from each 3-hour 
timepoint was randomly selected and combined to produce a representative sample of daily fecal movements. Fecal samples were weighed, 
combined with an appropriate volume of 10 mM Tris Buffer (pH=8.0), and homogenized using a FastPrep (MP Biomedicals) for 2 minutes at 
4.0 m/s.  500mL of the resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for Soil (MP Biomedicals) following 
manufacturer‟s directions and DNA concentration was assayed by spectrophotometry.  
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FIGURE 7 The recovery of DNA from the feces of individual Sprague-Dawley rats consuming C diet as a function of time.  Fecal samples were 
collected from individual rats at 3-hour increments during the dark cycle over a 12-hour period. One fecal pellet from each 3-hour timepoint was 
randomly selected and combined to produce a representative sample of daily fecal movements. Fecal samples were weighed, combined with an 
appropriate volume of 10 mM Tris Buffer (pH=8.0), and homogenized using a FastPrep (MP Biomedicals) for 2 minutes at 4.0 m/s.  500mL of 
the resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for Soil (MP Biomedicals) following manufacturer‟s 
directions and DNA concentration was assayed by spectrophotometry.  
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TABLE 8     Mean recovery of DNA extracted from the feces of untreated Sprague-Dawley rats as a  
    function of time  
Diet Mean ng DNA / gram feces Fold change 1 p value 2 
 day 1 day 43   
C 1.34105  2.64104 1.19105  4.46104 0.888 0.485 
M 1.31105  4.99104 1.69105  1.07105 1.299 0.250 
R 1.10105  3.40E+04 9.28104  2.19E+04 0.844 0.250 
S 1.29105  5.71104 1.45105  2.52104 1.120 0.833 
1  Fold change indicates mean nanogram DNA / gram feces of day 43 divided by mean 
nanogram DNA / gram feces of day 1 
2  P-values calculated using paired samples t-test to compare means on day 1 and day 43 of 
study (SPSS 15.0 for Windows) 
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FIGURE 8    DNA per gram feces is not significantly affected by diet consumption. Over the course of the study, consumption of the R diet resulted 
in a nonsignificant decrease in nanograms DNA per gram feces (p = 0.250), from 1.10105 ng DNA at day 1 of study to 9.28104 ng DNA at day 43. 
Consumption of the C diet also caused a nonsignificant decrease in DNA per gram feces (p = 0.485), from 1.34105 ng DNA at day 1 to 1.19105 ng 
DNA at day 43. Rats consuming the M diet (p = 0.250) and S diet (p = 0.833) did see increases in DNA levels per gram feces over time, though both 
were nonsignificant. Consumption of the M diet caused a 1.299-fold increase in DNA per gram feces, increasing from 1.31105 ng DNA at day 1 of 
study to 1.69105 ng DNA at day 43 of study. Consuming the S diet caused a 1.12-fold increase in DNA per gram feces over time, increasing from 
1.29105 ng DNA at day 1 to 1.45105 ng DNA at day 43. Statistics calculated using paired samples t-test (SPSS 15.0 for Windows). 
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FIGURE 9     Nanograms (ng) DNA extracted per gram feces from DSS-treated Sprague-Dawley rats consuming R diet over a 43-day 
period. Fecal samples were collected from individual rats at 3-hour increments during the dark cycle over a 12-hour period spanning the 
hours of 7 p.m. to 7 a.m.. Prior to processing, one fecal pellet from each 3-hour timepoint of the collection period was combined in a clean 
2mL microtube to produce a representative sample of fecal movements. Fecal samples were weighed in 15mL plastic tubes and combined 
with 5mL of 10mM Tris-HCl buffer (pH=8.0).  Samples were homogenized using a FastPrep (MP Biomedicals) for 2 minutes at 4.0 m/s.  
500mL of the resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for Soil (MP Biomedicals) following 
manufacturer‟s directions.  
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FIGURE 10     Nanograms (ng) DNA extracted per gram feces from DSS-treated Sprague-Dawley rats consuming M diet over a 43-day 
period. Fecal samples were collected from individual rats at 3-hour increments during the dark cycle over a 12-hour period spanning the 
hours of 7 p.m. to 7 a.m.. Prior to processing, one fecal pellet from each 3-hour timepoint of the collection period was combined in a clean 
2mL microtube to produce a representative sample of fecal movements. Fecal samples were weighed in 15mL plastic tubes and combined 
with 5mL of 10mM Tris-HCl buffer (pH=8.0).  Samples were homogenized using a FastPrep (MP Biomedicals) for 2 minutes at 4.0 m/s.  
500mL of the resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for Soil (MP Biomedicals) following 
manufacturer‟s directions.  
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FIGURE 11     Nanograms (ng) DNA extracted per gram feces from DSS-treated Sprague-Dawley rats consuming S diet over a 43-day 
period. Fecal samples were collected from individual rats at 3-hour increments during the dark cycle over a 12-hour period spanning the 
hours of 7 p.m. to 7 a.m.. Prior to processing, one fecal pellet from each 3-hour timepoint of the collection period was combined in a clean 
2mL microtube to produce a representative sample of fecal movements. Fecal samples were weighed in 15mL plastic tubes and combined 
with 5mL of 10mM Tris-HCl buffer, (pH=8.0).  Samples were homogenized using a FastPrep (MP Biomedicals) for 2 minutes at 4.0 m/s.  
500mL of the resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for Soil (MP Biomedicals) following 
manufacturer‟s directions.  
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FIGURE 12      Nanograms (ng) DNA extracted per gram feces from DSS-treated Sprague-Dawley rats consuming C diet over a 43-day 
period. Fecal samples were collected from individual rats at 3-hour increments during the dark cycle over a 12-hour period spanning the 
hours of 7 p.m. to 7 a.m.. Prior to processing, one fecal pellet from each 3-hour timepoint of the collection period was combined in a clean 
2mL microtube to produce a representative sample of fecal movements. Fecal samples were weighed in 15mL plastic tubes and combined 
with 5mL of 10 mM Tris-HCl buffer (pH=8.0).  Samples were homogenized using a FastPrep (MP Biomedicals) for 2 minutes at 4.0 m/s.  
500mL of the resulting homogenate was used for DNA extraction with the Fast DNA Spin Kit for Soil (MP Biomedicals) following 
manufacturer‟s directions.  
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  TABLE 9    Mean recovery of DNA extracted from the feces of DSS-treated Sprague-Dawley  
 rats as a function of time 
Diet Mean ng DNA / gram feces Fold Change 
1 
p value 2 
 day 1 day 43   
C 1.12104  3.78103 9.29103  4.20103 0.83 0.514 
M 7.37103  6.95103 1.84104  2.34104 2.50 0.207 
R 1.37104  3.51103 1.78104  1.62104 1.30 0.560 
S 1.28104  1.70103 1.77104  2.72103 1.39 0.125 
1 Fold change indicates mean nanogram DNA / gram feces of day 43 divided by mean 
nanogram DNA / gram feces of day 1 
2 p-values calculated using paired samples t-test to compare means on day 1 and day 43 of 
study (SPSS 15.0 for Windows) 
 
 
 
 
 
 
 
  
 
121 
 
1.00E+02
1.00E+04
1.00E+06
0 5 10 15 20 25 30 35 40 45 50
Time (days)
n
g
 D
N
A
/g
 f
e
c
e
s
C Diet
M Diet
R Diet
S Diet
 
FIGURE 13    DNA per gram feces is not significantly affected by diet consumption. Over the course of the study, consumption of the 
R diet resulted in a nonsignificant increase in nanograms DNA per gram feces (p = 0.560), from 1.37104 ng DNA at day 1 of study 
1.78104 ng DNA at day 43. Consumption of the C diet caused a nonsignificant decrease in DNA per gram feces (p = 0.514), from 
1.12104 ng DNA at day 1 to 9.29103 ng DNA at day 43. Rats consuming the M diet (p = 0.207) and S diet (p = 0.125) did see 
increases in DNA levels per gram feces over time, though both were nonsignificant. Consumption of the M diet caused a 2.50-fold 
increase in DNA per gram feces, increasing from 7.37103 ng DNA at day 1 of study to 1.84104 ng DNA at day 43 of study. 
Consuming the S diet caused a 1.39-fold increase in DNA per gram feces over time, increasing from 1.28104 ng DNA at day 1 to 
1.77104 ng DNA at day 43. Statistics calculated using paired samples t-test (SPSS 15.0 for Windows). 
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FIGURE 14    16S rRNA gene copies/g feces of bifidobacteria increase over time during consumption of 
R diet, M diet, and C diet.  DNA was extracted from fecal material using the Soil Kit (MP Biomedicals).  
Quantitative PCR using 16S rRNA taxon-specific primers was used to determine the number of 
Bifidobacterium-group 16S rRNA gene copies per gram feces.  Consumption of the R diet caused a 26.54-
fold increase in bifidobacteria at the end of the study, with a final concentration of 5.75108 16S rRNA 
gene copies/g feces (p = 0.00).  Bifidobacteria 16S rRNA gene copies/g feces peaked at day 36 of the 
study, causing a 101-fold increase in comparison to day 1 (p = 0.00).  Consumption of the M diet and C 
diet resulted in 9.61 and 1.68-fold increases in bifidobacteria, respectively.  (A) displays results of dietary 
consumption with error bars ( 1 standard deviation), while (B) displays results of dietary consumption 
without error bars.  Statistics calculated using paired samples t-test (SPSS 15.0 for Windows). 
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TABLE 10    Mean bifidobacteria 16S rRNA gene copies/g feces on day 1 and day 43 of 
study 
Diet Mean 16S rRNA gene copies/g feces Fold change1 p value2 
 day 1 day 43   
C 4.21106  7.40106 7.06106  6.83106 1.68 0.001 
M 1.69107  1.31107 1.63108  1.94108 9.61 0.009 
R 2.17107  1.99107 5.75108  4.46108 26.54 0.000 
S 2.66108  7.75108 3.32106  5.19106 0.01 0.114 
1 Fold change indicates mean 16S rRNA gene copies/g feces of day 43 divided by mean 
16S rRNA gene copies/g feces of day 1 
2 p-values calculated using paired samples t-test to compare means on day 1 and day 43 of  
study (SPSS 15.0 for Windows) 
  
 
124 
3
4
5
6
7
8
9
10
11
0 5 10 15 20 25 30 35 40 45 50
Day of Study
L
o
g
 1
6
S
 r
R
N
A
 g
e
n
e
 c
o
p
ie
s
/g
ra
m
 f
e
c
e
s
Resistant Starch Diet
Soluble Corn Fiber Diet
Cellulose Diet
Mixed Diet
 
FIGURE 15     Log10 16S rRNA gene copies/g feces of bifidobacteria increase over time during consumption of R diet, M diet, and C 
diet.  DNA was extracted from fecal material using the Soil Kit (MP Biomedicals).  Quantitative PCR using 16S rRNA taxon-specific 
primers was used to determine the number of Bifidobacterium-group 16S rRNA gene copies per gram feces.  Consumption of the R 
diet caused a significant increase in bifidobacteria at the end of the study, with a final concentration of 8.76 log (16S rRNA gene 
copies/g feces) (p-value = 0.00).  Bifidobacteria numbers peaked at day 36 of the study, with a concentration of 9.04 log (16S rRNA 
gene copies/g feces)  (p-value = 0.00).  Consumption of the M diet and C diet resulted final bacterial concentrations of 8.21 and 6.84 
log (16S rRNA gene copies/g feces), respectively.  Statistics calculated using paired samples t-test (SPSS 15.0 for Windows). 
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FIGURE 16     Boxplot analysis of the distribution of log10 16S rRNA gene copies/g feces of bifidobacteria over 
time. DNA was extracted from fecal material using the Soil Kit (MP Biomedicals).  Quantitative PCR using 16S 
rRNA taxon-specific primers was used to determine the number of Bifidobacterium-group 16S rRNA gene copies 
per gram feces. Boxplots were constructed to display the distribution of samples from each day of fecal collection. 
Due to experimental design, sample size was variable and is displayed below each boxplot. Paired sample t-tests 
were utilized to determine which days of study were significantly different from baseline (day 1), when rats were 
all consuming a standard chow diet (Harlan). Asterisk (*) denotes a significant difference from day one (p  0.05). 
Figures represent consumption of the following: (A) C diet; (B) M diet; (C) R diet; and (D) S diet. (A) During 
consumption of the C diet, significant differences from day 1 were observed on day 28 (p = 0.026), day 36 (p = 
0.027), day 37 (p = 0.05), and day 43 (p = 0.001). Day 39 of C diet consumption caused a significant decrease in 
bifidobacteria in comparison to day 1 (p = 0.015). (B) Apart from days 22 and 35, bifidobacteria levels were 
significantly different from baseline throughout the study (p < 0.05). Bifidobacteria levels were significantly lower 
than baseline only on day 7 (p = 0.000). (C) R diet consumption caused significantly different bifidobacteria levels 
throughout the course of the study (p < 0.05). (D) Day 22 (p = 0.001), day 35 (0.001), and day 36 (p = 0.001) of S 
diet consumption was found to be significantly different from day 1. Statistical analysis performed using SPSS 
15.0 for Windows. 
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FIGURE 17     No significant increase of lactobacilli 16S rRNA gene copies/g feces 
was observed during consumption of four fermentable diets over a 43-day period.  
DNA was extracted from fecal material using the Soil Kit (MP Biomedicals).  
Quantitative PCR using 16S rRNA taxon-specific primers was used to determine the 
number of Lactobacillus-group 16S rRNA gene copies per gram feces.  Consumption 
of the S diet (p = 0.018), M diet (p = 0.004), and C diet (p = 0.037) caused a 
significant decrease in lactobacilli populations.  Consumption of the R diet resulted in 
no significant difference between lactobacilli populations on day 1 and day 43 (p = 
0.628).  (A) displays results of dietary consumption with error bars ( 1 standard 
deviation).  (B) displays results of dietary consumption without error bars.  Statistics 
calculated using paired samples t-test (SPSS 15.0 for Windows). 
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TABLE 11    Mean lactobacilli 16S rRNA gene copies/g feces at day 1 and day 43 of study 
Diet 16S rRNA gene copies/g feces Fold Change1 p value2 
 day 1 day 43   
C 1.861010  1.541010 1.331010  1.51010 0.71 0.037 
M 5.14109  5.89109 1.78108  1.91108 0.03 0.004 
R 1.371010  1.841010 1.211010  1.21010 0.86 0.628 
S 2.761010  5.871010 2.26109  4.21109 0.08 0.018 
1 Fold change calculated by: mean 16S rRNA gene copies/g feces on day 43 divided by 
mean 16S rRNA gene copies/g feces on day 1 
2 p-values calculated using paired samples t-test to compare means at day 1 and day 43 of 
study (SPSS 15.0 for Windows)
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FIGURE 18     No significant increase of lactobacilli Log10 16S rRNA gene copies/g feces was observed during 
consumption of four fermentable diets over a 43-day period.  DNA was extracted from fecal material using the Soil 
Kit (MP Biomedicals).  Quantitative PCR using 16S rRNA taxon-specific primers was used to determine the number 
of Lactobacillus-group 16S rRNA gene copies per gram feces.  Consumption of the S diet caused a significant 
decrease in lactobacilli, with 9.93 log (16S rRNA gene copies/g feces) present at day 43 of the study (p = 0.018).  
The M diet also caused a significant decrease in lactobacilli populations, with a final population of 8.24 log (16S 
rRNA gene copies/g feces) (p = 0.004).  C diet consumption also decreased lactobacilli populations over time, 
resulting in 7.74 log (16S rRNA gene copies/g feces) at day 43 of the study (p = 0.037).  Consumption of the R diet 
resulted in no significant difference between lactobacilli populations on day 1 and day 43 (p = 0.628).    
Statistics calculated using paired samples t-test (SPSS 15.0 for Windows). 
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FIGURE 19   Boxplot analysis of the distribution of log10 16S rRNA gene copies/g feces of lactobacilli 
over time. DNA was extracted from fecal material using the Soil Kit (MP Biomedicals).  Quantitative PCR 
using 16S rRNA taxon-specific primers was used to determine the number of Lactobacillus-group 16S 
rRNA gene copies per gram feces. Boxplots were constructed to display the distribution of samples from 
each day of fecal collection. Due to experimental design, sample size was variable and is displayed below 
each boxplot. Paired sample t-tests were utilized to determine which days of study were significantly 
different from baseline (day 1), when rats were all consuming a standard chow diet (Harlan). Asterisk (*) 
denotes a significant difference from day one (p  0.05). Figures represent consumption of the following: 
(A) C diet; (B) M diet; (C) R diet; and (D) S diet. (A) During consumption of the C diet, significant 
differences (p < 0.05) from day 1 were observed on each day of study, except for day 21 (p = 0.171) and 
day 35 (p = 0.154). (B) Significant variation in lactobacilli levels were observed on day 7 (p = 0.000), day 
14 (p = 0.043), day 29 (p = 0.001), day 30 (p = 0.001), day 35 (0.004), and day 43 (p = 0.004). (C) Only 
day 22 of R diet consumption caused significantly different lactobacilli levels throughout the course of the 
study (p = 0.025). (D) Day 7 (p = 0.018), day 14 (0.046), and day 36 (p = 0.002), day 37 (p = 0.000), day 
39 (p = 0.014), and day 43 (p = 0.018) of S diet consumption was found to be significantly different from 
day 1. Statistical analysis performed using SPSS 15.0 for Windows. 
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STATISTICAL ANALYSIS OF THE EFFECTS OF RESISTANT STARCH AND 
SOLUBLE CORN FIBER CONSUMPTION ON LACTOBACILLI AND 
BIFIDOBACTERIA PROLIFERATION USING A LINEAR MIXED MODEL 
FORMULATION 
 
Analysis Performed by Dr. Nikolay Bliznyuk 
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FIGURE 20        Resistant starch (R) diet significantly increases log (copy number/gram feces) of 
bifidobacteria over a 50-day period.  Consumption of the resistant starch (R) diet significantly increased 
the bifidobacteria copy # per gram feces over time (p = 0.005).  Increases in the cellulose (C) diet (p = 
0.484) and mixed (M) diet (p = 0.279) were not significant.  Consumption of the soluble corn fiber (S) diet 
caused a substantial washout of native bifidobacteria species, which were unable to fully reestablish within 
the experimental timeframe. 
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FIGURE 21    Resistant starch (R) diet significantly increases log (copy number/gram feces) of 
lactobacilli over 50-day period.  Consumption of the resistant starch (R) diet significantly increased the 
lactobacilli copy # per gram feces over time (p = 0.005).  Consumption of the cellulose (C) diet did not 
cause a significant increase over time (p = 0.701).  Rats consuming the mixed (M) diet and soluble corn 
fiber (S) diet both experienced severe decreases in lactobacilli populations after introduction of the diets.  
M rats were unable to fully reestablish lactobacilli numbers over the course of the study.  While rats 
consuming the S diet were able to reestablish lactobacilli, their numbers began decreasing towards the end 
of the study, with no significant increase in bacterial numbers resulting by day 50.   
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TABLE 12   Utilization of resistant starch in retrograded native tapioca, corn and waxy corn starches by Bifidobacterium1 
1 Table populated with data from Wronkowska et al. (199) 
 
 
Type Compound Characteristics Source Experimental Design Assessment Method Result References 
In vitro 
Retrograded 
Tapioca RS3 
National 
Starch 
Warsaw, 
Poland 
RS3 was inoculated with 
3 bifidobacteria strains; 
incubated anaerobically 
for  24 hours 
Plate Count 
Method 
(CFU/ml) 
 
B. pseudolongum KSI9: 8.49 ± 
0.11 log CFU/mL (significant 
increase over glucose control) 
 
B.animalis KS20a1: NSD 
 
B. breve KN14: 6.01 ± 0.21 
log CFU/mL (significant 
increase over glucose control) 
 
(199) 
In vitro 
Retrograded 
Corn RS3 
National 
Starch 
Warsaw, 
Poland 
RS3 was inoculated with 
3 bifidobacteria strains; 
incubated anaerobically 
for  24 hours 
Plate Count 
Method 
(CFU/ml) 
 
B. pseudolongum KSI9: NSD 
B.animalis KS20a1: 7.74 ± 
0.83 log CFU/mL (significant 
increase over glucose control) 
 
B. breve KN14: 8.83 ± 0.30 
log CFU/mL (significant 
increase over glucose control) 
 
(199) 
In vitro 
Retrograded 
Waxy  Corn RS3 
National 
Starch 
Warsaw, 
Poland 
RS3 was inoculated with 
3 bifidobacteria strains; 
incubated anaerobically 
for  24 hours 
Plate Count 
Method 
(CFU/ml) 
 
B. pseudolongum KSI9: 6.01 ± 
0.21 log CFU/mL (significant 
increase over glucose control) 
 
B.animalis KS20a1: 8.83 ± 
0.30 log CFU/mL (significant 
increase over glucose control) 
 
B. breve KN14: 8.67 ± 0.34 
log CFU/mL (significant 
increase over glucose control) 
 
(199) 
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TABLE 13    Bacterial strains used in this study 
Strain Origin Source 
Bifidobacteria   
     Bifidobacterium longum DJ010A Human infant intestine Dan O‟Sullivan 
     Bifidobacterium adolescentis ATCC 15703 Human adult feces ATCC 1 
     Bifidobacterium animalis subsp.  animalis NRRL B-41406 Rat feces ARS 2 
     Bifidobacterium animalis subsp.  lactis NRRL B-41405 Yogurt ARS 
     Bifidobacterium bifidum NRRL B-41410 Human infant intestine ARS 
     Bifidobacterium bifidum NRRL B-1976 Not provided ARS 
     Bifidobacterium breve NRRL B-41408 Human infant intestine ARS 
     Bifidobacterium infantis NRRL B-41661 Human infant intestine ARS 
     Bifidobacterium longum NRRL B-41409 Human adult intestine ARS 
     Bifidobacterium suis NRRL B-41407 Pig feces ARS 
Lactobacilli   
     Lactobacillus acidophilus ATCC 4356 Human ARS 
     Lactobacillus animalis NRRL B-14176 Dental plaque of baboon ARS 
     Lactobacillus casei ATCC 393 Dairy (cheese) ATCC 
     Lactobacillus casei subsp.  casei NRRL B-442 Dairy (Emmental cheese) ARS 
     Lactobacillus gasseri ATCC 19992 Feces ATCC 
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TABLE 13    (Continued) 
Strain Origin Source 
     Lactobacillus johnsonii ATCC 11506 Not provided ATCC 
     Lactobacillus pentosus NRRL B-227 Not provided ATCC 
     Lactobacillus rhamnosus NRRL 442 Not provided ARS 
     Lactobacillus rhamnosus ATCC 7469 Not provided ATCC 
     Lactobacillus rhamnosus NRRL B-14176 Not provided ARS 
     Lactobacillus salivarius subsp.  salivarius NRRL 1949 Not provided ARS 
1 ATCC: American Type Culture Collection; ARS: Agricultural Research Service 
2 ARS: Agricultural Research Service 
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TABLE 14     Bacterial proliferation on Garche agar plates containing 1% resistant starch or 1% soluble corn  fiber after 72 h 
Strain Strain Growth on1: 
  Resistant Starch  Soluble Corn Fiber  
Bifidobacterium adolescentis ATCC 15703 + +++ 
B. animalis subsp.  animalis NRRL B-41406 + ++ 
B. animalis subsp.  lactis NRRL B-41405 + ++ 
B. bifidum NRRL B-41410 ++ ++ 
B. bifidum NRRL B-1976 + ++ 
B. breve NRRL B-41408 + ++ 
B. infantis NRRL B-41661 + +++ 
B. longum NRRL B-41409 + + 
B. suis NRRL B-41407 + ++ 
Lactobacillus acidophilus ATCC 4356 + + 
L. animalis NRRL B-14176 + + 
L. casei ATCC 393 ++ ++ 
L. casei subsp.  casei NRRL B-441 ++ ++ 
L. gasseri ATCC 19992 + ++ 
L. johnsonii ATCC 11506 + + 
L. pentosus NRRL B-227 ++ ++ 
L. rhamnosus NRRL B-442 +++ +++ 
L. rhamnosus ATCC 7469 ++ +++ 
L. rhamnosus NRRL B-14176 + + 
L. salivarius subsp.  salivarius NRRL 1949 ++ ++ 
 1 Relative ability (+, ++, +++) or inability (-) of strains to utilize carbon source
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TABLE 15    RCA plate counts (CFU/mL) of bifidobacteria cultivated in Garche broth containing 1% resistant starch or 1% lactose 
at 0 and 10 hours post inoculation 
Species Strain Carbon Source 
  Resistant starch Lactose 
  hour 0 2 hour 10 2 fold 
change 
p-value3 hour 0 2 hour 10 2 
fold 
change 
p-value3 
B. longum DJ010A 4.1110
6  
1.75106 
1.50107  
7.45106 3.65 0.030 
3.20106  
5.03105 
5.51108  
3.18108 172.19 0.008 
B. 
adolescentis 
ATCC 
15703 
7.27106  
1.95106 
6.68106  
6.18106 0.92 0.864 
4.04106  
2.61106 
1.72108  
4.57107 42.57 0.000 
B. infantis 
NRRL B-
41661 
7.93106  
1.41106 
1.12107  
4.45106 1.41 0.200 
9.23106  
2.90106 
8.50108  
2.49108 92.09 0.000 
B. bifidum 
NRRL B-
41410 
1.84106  
1.07106 
1.94107  
3.37107 105.43 0.000 
1.83106  
1.07106 
2.81108  
2.05108 153.55 0.021 
B. animalis 
animalis 
NRRL B-
41406 
7.20105  
2.65105 
6.78107  
8.70105 9.42 0.008 
2.23105  
3.54104 
5.08106  
1.10106 22.78 0.000 
 1 Carbon source equates to 1% (w/v) of Garche medium  
 2 Values indicate mean CFU/mL 
 3 p-values calculated using paired sample t-test (α = 0.05); SPSS 15.0 for Windows 
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FIGURE 22     Cultivation of bifidobacteria in Garche broth supplemented with 1% resistant starch increases bacterial growth after 10 hour incubation 
period.  Stock strains were cultured anaerobically for 24 hours in Reinforced Clostridial Medium (RCM) (Thermo Fisher Scientific) at 37°C.  Strains 
were cultivated in Garche media containing 1% (w/v) resistant starch for a 10-hour timeframe.  At hours 0 and 10, serial dilutions were plated on 
Reinforced Clostridial Agar (RCA) plates and incubated anaerobically at 37°C for 72 hours.  Plate counts (CFU/mL) were conducted for hours 0 and 10 
post inoculation (n = 6 plates per timepoint).  B. longum DJ010A (p = 0.030), B. bifidum NRRL B-41410 (p = 0.000), and B. animalis subsp.  animalis 
(p = 0.008) all displayed significant increases in growth after ten hour incubation.  B. infantis NRRL B-41661 exhibited a nonsignificant increase after 
10 hours (p = 0.200) B. adolescentis ATCC 15703 did not experience an increase in growth after inoculation (fold change = 0.9188).  Error bars 
represent one standard deviation from the mean. Michelin Guide scale used to indicate significance.  Statistics calculated using SPSS 15.0 for Windows.  
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FIGURE 23    Cultivation of bifidobacteria in Garche broth supplemented with 1% lactose increases bacterial growth after 10 hour incubation period.  
Stock strains were cultured anaerobically for 24 hours in Reinforced Clostridial Medium (RCM) (Thermo Fisher Scientific) at 37°C.  Strains were 
cultivated in Garche media containing 1% (w/v) resistant starch for a 10-hour timeframe.  At hours 0 and 10, serial dilutions were plated on Reinforced 
Clostridial Agar (RCA) plates and incubated anaerobically at 37°C for 72 hours.  Plate counts (CFU/mL) were conducted for hours 0 and 10 post 
inoculation (n = 6 plates per timepoint).   B. longum DJ010A (p = 0.008), B. adolescentis ATCC 15703 (p = 0.000), B. infantis NRRL B-41661 (p = 
0.000), B bifidum NRRL B-41410 (p = 0.021), and B. animalis subsp.  animalis NRRL B-41406 (p = 0.000) all exhibited significant increases in 
growth after 10 hours.  Error bars indicate one standard deviation from the mean. Michelin Guide scale used to indicate significance.  Statistics  
calculated using SPSS 15.0 for Windows.
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TABLE 16   Proliferation (CFU/mL) of B. longum and B. bifidum after 24 hour cultivation in Garche broth 
containing 1% resistant starch and 1% soluble corn fiber  
Species Strain Carbon Source  
  resistant starch (CFU/mL) soluble corn fiber (CFU/mL) 
B. longum NRRL B-41409 4.0106 1.02107 
B. bifidum NRRL B-41410 4.0107 2.25108 
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